Beyond Weight Loss

Incretin Companion Care and the Emergence of *Pharmacoadaptive* Nutrition



José M. López, BSc, MD, PhD, LLD (C)

BEYOND WEIGHT LOSS

Incretin Companion Care and the Emergence of Pharmacoadaptive Nutrition

A scientific, clinical, formulation and innovation framework for the GLP-1 era

José M. López, BSc, MD, PhD, LLD(C)

INTABIOTECH

Scientific Monography · Publication Edition

Evidence reviewed through 19 August 2026

INTABIOTECH Publishing Service

Botiguers, 3, 2nd Floor, 46980

Paterna · Valencia · Spain

FRONT MATTER

Editorial Note

This edition consolidates successive research and strategy drafts into a single publishable scientific monograph. It is designed for academic, clinical, regulatory and innovation audiences.

This monograph is a translational scientific work. It is not individualized medical advice, a clinical practice guideline, a regulatory authorization, a legal opinion, or a freedom-to-operate opinion. Decisions concerning prescription medicines, pregnancy, suspected adverse events, clinically significant dehydration, renal disease, gallbladder disease, severe gastrointestinal symptoms, nutritional deficiencies or other medical conditions require appropriate professional assessment.

PUBLIC-EDITION IP BOUNDARY

Detailed proprietary composition ranges, process parameters, sensory thresholds, algorithmic cut-offs and preferred embodiments that could compromise future intellectual-property protection have been intentionally excluded or generalized. The scientific concepts are presented openly; potentially enabling R&D detail should remain in a separate confidential dossier pending formal prior-art and patent review.

The literature and market landscape in incretin-based obesity treatment is evolving rapidly. Regulatory status, prescribing information, product portfolios and patent positions should therefore be re-verified at the time of commercial or clinical implementation.

The Author.

August 2026

PREFACE

Why This Book Now

The central problem created by successful incretin pharmacotherapy is no longer simply whether patients can lose substantial weight, but whether that weight loss can occur while nutritional, muscular, skeletal and functional resilience are preserved.

Modern incretin therapies have changed the practical ceiling of pharmacological weight reduction. Their success has also exposed a structural gap in conventional nutrition: appetite and tolerated food volume may contract far more rapidly than essential requirements for amino acids, micronutrients, fluids and mechanical stimulation of muscle and bone. The original manuscript identified this mismatch as nutritional compression and progressively expanded the response from Incretin Companion Nutrition to Incretin Companion Care.

The purpose of this publication is not to promote supplements around a fashionable drug class. It is to propose a disciplined framework for pharmacologically adapted precision nutrition: identify the physiological problem, phenotype the patient, define the treatment phase, select the minimum rational intervention, measure a clinically meaningful outcome, and stop when the problem belongs to medicine rather than nutrition.

CENTRAL THESIS

The next competitive frontier is not kilograms lost. It is the quality of weight loss, the quality of adaptation during treatment, and the durability of therapeutic benefit after treatment intensity changes.

ABSTRACT

Extended Abstract

A concise synthesis of the monograph's clinical thesis, evidence hierarchy, product logic and research agenda.

The rapid expansion of glucagon-like peptide-1 receptor agonists and related incretin-based therapies has transformed obesity treatment, producing weight reductions that were previously difficult to achieve without metabolic surgery. Their success has exposed a second therapeutic challenge: preserving physiological resilience when appetite, food intake and tolerated meal volume decline faster than requirements for essential nutrients and functional stimuli. This monograph proposes Incretin Companion Nutrition (ICN) and the broader construct of Incretin Companion Care (ICC) as translational frameworks spanning obesity medicine, clinical nutrition, exercise physiology, gastroenterology, dermatology, oral health, food technology, digital phenotyping and long-term weight maintenance. It introduces nutritional compression, anabolic density, quality of weight loss, adaptive reserve gap, effective nutrient delivery, therapeutic exit readiness and retention of therapeutic benefit as research constructs rather than validated clinical indices. The evidence supports immediate emphasis on adequate complete protein, resistance exercise, hydration, gastrointestinal tolerance, risk-based micronutrient management and targeted investigation of creatine, essential amino-acid microdelivery and other muscle-resilience approaches. Hair, skin, bone, oral health and microbiome-related interventions require more selective evidence and should not be overclaimed. The framework further argues that the optimal nutritional architecture should change across treatment phases: low-volume nutrient delivery during severe appetite suppression, functional preservation during active loss, and higher-structure high-protein/high-fibre eating during maintenance or pharmacological transition. Finally, the monograph examines the rapidly expanding competitive and patent landscape and proposes Pharmacoadaptive Nutrition as a broader discipline concerned with nutrition deliberately engineered around predictable physiological changes induced by pharmacotherapy. The governing principle is precision rather than ingredient accumulation: the right intervention, for the right phenotype, at the right phase, with the right endpoint.

Keywords: GLP-1; incretin therapy; semaglutide; tirzepatide; obesity; clinical nutrition; body composition; lean mass; protein; creatine; gastrointestinal tolerance; hydration; nutricosmetics; weight maintenance; pharmacoadaptive nutrition.

Proposed conceptual vocabulary

Construct	Working definition
Nutritional Compression	Reduction in energy intake and tolerated food volume that outpaces the proportional reduction in essential nutrient requirements.
Anabolic Density	Amount of useful anabolic substrate successfully delivered per unit of tolerated gastric volume.
Quality of Weight Loss	Reduction of excess adiposity while preserving physiologically valuable tissue, function and nutritional status.
Adaptive Reserve Gap	Mismatch between the speed of pharmacologically induced physiological change and the individual's capacity for structural, nutritional and functional adaptation.
Effective Nutrient Delivery	Nutrient content adjusted for the fraction actually consumed and longitudinal adherence.
Therapeutic Exit Readiness	Preparedness to maintain nutritional, muscular and behavioural gains if pharmacological intensity is reduced or withdrawn.
Retention of Therapeutic Benefit	Proportion of the achieved therapeutic benefit that remains after treatment transition.
Pharmacoadaptive Nutrition	Proposed broader discipline of nutrition deliberately adapted to predictable physiological consequences and phases of pharmacotherapy.

CONTENTS

Contents

The five original instalments are reorganized here into thirteen coherent chapters plus appendices.

CONTENT TABLE

CHAPTER 01

From Weight Loss to Quality of Weight Loss

The scientific objective is shifting from maximizing change on the scale to optimizing what is lost, what is preserved and how the patient functions throughout treatment.

The next problem in obesity pharmacotherapy is not weight-loss efficacy

The first generation of modern incretin obesity trials was necessarily dominated by one question: how much weight can pharmacotherapy remove? That question has largely been answered. Semaglutide and tirzepatide have demonstrated levels of weight reduction that were previously difficult to obtain without metabolic surgery, and modern incretin therapies are increasingly embedded within long-term obesity management.

The clinically more interesting question is now changing. It is no longer simply:

How much weight can the patient lose?

It should increasingly become:

What exactly is being lost, what physiological resources are being preserved, and what nutritional support is required while the loss is occurring?

This distinction is fundamental.

Body weight is not a tissue. It is an aggregate measurement encompassing adipose tissue, skeletal muscle, organs, extracellular and intracellular water, glycogen, bone and connective tissue. A therapy may therefore generate an excellent change in body weight while patients differ substantially in muscle function, nutrient adequacy, hydration, physical performance and quality of life.

This is why the emerging debate about “muscle loss from GLP-1 drugs” requires precision. In the DXA sub study of SURMOUNT-1, approximately three quarters of tirzepatide-associated weight loss was fat mass and approximately one quarter lean mass. That finding should neither be dismissed nor sensationalized. DXA-derived lean mass is not synonymous with skeletal muscle, and loss of lean tissue during weight reduction does not automatically constitute sarcopenia. Nevertheless, the absolute loss becomes clinically more consequential in older adults, patients with low baseline muscular reserve, rapid weight loss, inactivity or inadequate protein intake.

The relevant objective is therefore not “zero lean-mass loss”, which may be physiologically unrealistic during major weight reduction. The objective is preservation of muscle quantity, quality, strength and function to the greatest achievable extent.

This is already reflected in the direction of contemporary European guidance, which emphasizes physical function and muscle preservation rather than interpreting BMI or weight alone as sufficient markers of successful obesity treatment.

Evidence anchor: Wilding et al. (2021); Jastreboff et al. (2022); Dobbie et al. (2026).

Nutritional compression: a useful framework for the GLP-1 era

We propose the term **nutritional compression** to describe one of the central nutritional consequences of successful incretin pharmacotherapy. The concept is straightforward.

GLP-1 and related incretin therapies suppress appetite, influence food reward and food preferences, and delay gastric emptying to varying degrees. Energy intake can therefore fall substantially. Requirements for many essential nutrients, however, do not decrease in parallel with caloric intake. A 30% reduction in caloric intake does not imply that a patient suddenly requires 30% less leucine, iron, calcium, vitamin B12, thiamine, zinc or essential amino acids.

This creates what may be termed the **Nutritional Compression Gap** (NCG):

NCG = contraction in food/energy intake − proportional reduction in essential nutrient requirements.

The NCG is proposed here as a conceptual framework rather than a validated clinical index. Its practical significance is considerable.

As appetite decreases, every tolerated gram and milliliter of food acquires greater nutritional importance. The therapeutic diet must therefore evolve from conventional calorie restriction toward high nutrient density per unit of tolerated volume. This is a major conceptual shift.

For decades, obesity nutrition focused predominantly on preventing excessive energy intake. In successful incretin treatment, some patients develop the opposite operational problem: how to deliver enough nutrition through a markedly reduced eating window and diminished appetite.

This does not make incretin treatment physiologically equivalent to bariatric surgery. Most GLP-1 therapies are not intrinsically malabsorptive procedures. The major mechanism appears to be decreased intake, altered eating behavior and gastrointestinal intolerance, although specific effects on absorption have been reported and remain under investigation. A 2026 review encompassing six studies and more than 480,000 individuals reported clinically recorded nutritional deficiencies

during GLP-1RA therapy but importantly acknowledged that the underlying studies were predominantly observational and could not establish that the medication itself caused each deficiency. That distinction is essential. Association is sufficiently strong to justify monitoring; it is not sufficiently strong to justify indiscriminate supplementation.

Evidence anchor: Mozaffarian et al. (2025); Urbina et al. (2026).

The field has moved from theory to active clinical development

The question is no longer whether preservation of nutritional and functional integrity during incretin-induced weight loss deserves scientific attention.

It does.

By mid-2026, the field has moved beyond theoretical concern. Dedicated trials are evaluating resistance exercise and protein during semaglutide or tirzepatide therapy, resistance training in established GLP-1 users, and creatine supplementation during GLP-1 receptor-agonist treatment. Clinical development programs are simultaneously testing pharmaceutical approaches designed to alter the partitioning of weight loss between adipose and lean tissues.

This is important for two reasons.

First, it confirms that body-composition quality has become a legitimate development endpoint in obesity pharmacotherapy.

Second, it creates a narrow but important window for nutrition science. If the nutritional industry responds merely with generic protein powders, multivitamins and products opportunistically labelled “GLP-1 support”, pharmaceutical development will move ahead while the nutritional sector remains scientifically superficial.

The objective should be considerably more ambitious.

Incretin Companion Nutrition (ICN) should be developed as an evidence-generating therapeutic-support platform. Its central task would not be to increase pharmacological appetite suppression, nor to mimic GLP-1 pharmacology. Its task would be to improve the biological quality of the weight loss already generated by pharmacotherapy.

Evidence anchor: ClinicalTrials.gov NCT07625202; NCT06885736; Dobbie et al. (2026).

The key development principle: protect what the drug is not intended to remove

Successful incretin pharmacotherapy preferentially reduces fat mass, but lean mass also decreases. In the SURMOUNT-1 DXA sub-study, approximately 75% of the weight lost with tirzepatide was fat mass and approximately 25% lean mass. Separate MRI

data from SURPASS-3 also indicate reductions in muscle volume accompanied by favorable reductions in muscle fat infiltration.

These findings require careful interpretation.

Lean mass measured by DXA is not synonymous with contractile skeletal muscle. It contains water and non-fat soft tissues, and some reduction is expected when body size decreases. Consequently, a simple number such as “kilograms of lean mass lost” cannot determine whether a treatment has induced clinically relevant sarcopenia.

The clinical concern becomes materially greater when loss of tissue is accompanied by deterioration in strength, physical performance, functional reserve, nutritional adequacy or the ability to recover from illness or inactivity.

The 2026 EASO–EFAD–ECPO consensus reflects precisely this broader transition toward nutritional and functional management during incretin treatment. This suggests that the real companion-nutrition target should be preservation of metabolically and functionally valuable tissue while allowing pharmacological loss of excess adipose tissue to continue. That is a tissue-selective objective.

Evidence anchor: Look et al. (2025); Sattar et al. (2025).

Quality of weight loss as the central therapeutic outcome

The GLP-1 revolution has demonstrated that substantial pharmacological weight reduction is possible. The next scientific objective should be more ambitious. A clinically optimal intervention should aim for:

- ***maximum reduction in pathological adiposity***
- ***while achieving***

minimum avoidable deterioration in muscle function, nutritional status, skeletal integrity, hydration and quality of life. That is a different therapeutic endpoint from kilograms lost. It is the quality of weight loss.

Incretin Companion Nutrition should therefore not compete with incretin pharmacotherapy. It should complete it. The opportunity is not to create another supplement trend around GLP-1 drugs. The opportunity is to create the nutritional discipline that high-efficacy obesity pharmacotherapy now requires.

Modern incretin therapy has created an unusual clinical paradox. Patients can eat substantially less without their physiological requirement for essential nutrients falling proportionally. This nutritional compression creates predictable vulnerabilities but also a major scientific opportunity.

The highest priorities are unlikely to be exotic. They begin with adequate high-quality protein, resistance exercise, nutritional screening, hydration and gastrointestinal tolerance. Innovation should then be layered on top of those foundations: compact

essential-amino-acid systems, creatine, selected HMB applications, individualized micronutrient delivery, symptom-specific gastrointestinal products, carefully evaluated mitochondrial-support compounds and evidence-based nutricosmetic strategies.

The scientific bar, however, must be higher than in conventional supplementation. Products intended for people undergoing pharmacologically induced weight loss should ultimately demonstrate more than ingredient bioavailability or generic health effects. They should demonstrate that they improve the quality, tolerability or functional consequences of weight loss itself. If that standard is adopted, the GLP-1 era could generate something much larger than another supplement category.

It could create a new discipline of pharmacologically adapted precision nutrition.

EDITORIAL SYNTHESIS

Body weight is an outcome; tissue composition and function are biological outcomes. Companion care becomes clinically meaningful only when it improves the latter without undermining the former.

CHAPTER 02

Muscle, Protein and Functional Reserve

Preserving skeletal muscle requires more than adding protein: substrate, training stimulus, patient phenotype, delivery volume and functional endpoints must be considered together.

Muscle preservation should become the cornerstone of companion nutrition

The most defensible nutritional priority during major pharmacological weight loss is preservation of skeletal muscle.

Contemporary GLP-1 nutritional guidance generally places protein requirements above conventional adult minimums during active weight reduction. The 2025 multidisciplinary US advisory proposed either individualized protein targets or, pragmatically, an approximate absolute target of 80–120 g/day in appropriate adults, while other recent consensus recommendations discuss intakes around 1.2–1.5 g/kg/day in relevant populations. These figures should not be mechanically applied to actual body weight in severe obesity; ideal, target or adjusted weight and individual renal, hepatic and metabolic circumstances must be considered. But total grams per day tell only part of the story.

Under severe appetite suppression, protein efficiency per eating event becomes important. A patient who tolerates only two or three small nutritional exposures per day may fail to reach an adequate anabolic amino-acid signal even if food quality is otherwise reasonable. This creates a specific formulation opportunity.

High-quality protein concentrates, protein hydrolysates and essential-amino-acid systems can deliver comparatively large quantities of indispensable amino acids in a small volume. Leucine deserves particular attention because of its role in amino-acid signaling and muscle protein synthesis, although the anabolic response ultimately requires the complete set of essential amino acids. General sports-nutrition evidence supports approximately 20–40 g of high-quality protein per feeding and adequate leucine content, but these data were not generated specifically in GLP-1-treated patients. That evidentiary distinction should define the research opportunity:

The rationale is strong; GLP-1-specific randomized evidence is still limited, and this is precisely where industry and academia should intervene.

Evidence anchor: Mozaffarian et al. (2025); Dobbie et al. (2026).

Protein alone will not solve the problem

One of the easiest commercial mistakes would be to conclude that the entire GLP-1 companion category can be reduced to “high-protein shakes”. It cannot.

A 300–400 mL high-protein beverage can itself become poorly tolerated in patients experiencing nausea, early satiety or marked delayed gastric emptying. High fat content may further reduce gastrointestinal tolerance in susceptible patients, while polyols and certain poorly absorbed sweeteners can aggravate bloating or diarrhea.

The clinically rational formulation therefore needs to optimize:

***protein density* × *amino-acid quality* × *tolerated volume* × *gastrointestinal compatibility*.**

This suggests a new design variable that conventional sports nutrition rarely prioritizes anabolic density per tolerated gastric volume.

For some patients, a compact serving of complete protein may be appropriate. For others, a still smaller essential-amino-acid formulation could theoretically provide greater anabolic efficiency for the tolerated volume. Whether such strategies preserve functional tissue better than conventional food-based approaches during incretin treatment remains a testable hypothesis. The commercial winner in this field will therefore probably not be the product with the largest number of ingredients.

It will be the formulation that patients can consistently tolerate and consume.

Essential amino acids — Tier II, potentially moving toward Tier I

Essential amino acids offer an important theoretical advantage under severe appetite suppression: they provide the amino acids required for muscle protein synthesis without the full caloric and volumetric load of a conventional meal.

Randomized calorie-restriction research in older adults with obesity has shown that whey/EAA-based nutritional systems can stimulate muscle protein synthesis and alter body-composition responses during weight loss.

We therefore propose an EAA micro-dose architecture rather than conventional BCAA supplementation. A low-volume complete-essential-amino-acid serving, with sufficient leucine to provide a meaningful anabolic signal, is a rational development direction. The optimal composition and serving size in incretin-treated patients remain to be experimentally determined.

The exact optimal amount in incretin-treated patients remains unknown and should be experimentally determined. This uncertainty is a development opportunity, not a weakness.

Leucine — useful as a signal, inadequate as a complete strategy

Leucine has an important role in initiating anabolic signaling, but leucine cannot construct muscle in the absence of adequate substrate from the other indispensable amino acids.

Human work has demonstrated that adding leucine to a low-protein formulation can enhance acute muscle protein-synthesis responses, but this should not be interpreted as evidence that isolated leucine replaces complete protein or EAAs.

For ICN development, leucine should therefore usually be considered: a formulation variable rather than a stand-alone product. The appropriate leucine content should be determined within the context of the complete EAA or protein matrix rather than treated as a stand-alone numerical target. A BCAA-only product would be scientifically inferior to a complete EAA system for this application.

Creatine monohydrate — Tier I research priority

Creatine may prove to be one of the most important molecules in the entire companion category.

Randomized trials outside the GLP-1 setting demonstrate improvements in strength and lean tissue when creatine is combined with resistance exercise, including in older adults.

More importantly, an actual registered study is now specifically examining creatine supplementation plus resistance training during GLP-1 receptor-agonist therapy. That changes its status. Creatine can no longer reasonably be described simply as an interesting speculative ingredient for GLP-1 users. It is now a direct clinical-development candidate. A pragmatic investigational range would be approximately:

3–5 g/day creatine monohydrate, without requiring a loading phase.

The primary outcome should not merely be DXA lean mass. It should include strength and physical performance because creatine can also increase intracellular water, which can influence lean-mass measurements independently of true contractile-protein accretion.

That methodological issue is particularly important in GLP-1 trials.

Evidence anchor: ClinicalTrials.gov NCT07625202; creatine evidence summarized in the cited literature.

HMB — Tier II, with greatest relevance in vulnerable phenotypes

β-Hydroxy-β-methylbutyrate deserves a more nuanced assessment.

Trials in older people have tested approximately 3 g/day, with some studies reporting improvements in muscle mass, strength or physical performance, particularly in vulnerable populations. HMB has also shown preservation of lean tissue during short

periods of bed rest, although other randomized studies have found no additional benefit over resistance training alone. This heterogeneity makes HMB unsuitable for universal inclusion merely because a patient uses semaglutide.

Its most rational target population may instead be:

older adults, low-muscle-reserve patients, periods of enforced inactivity, unusually rapid weight loss or patients who cannot reliably achieve adequate protein intake.

That phenotype deserves a dedicated GLP-1 trial.

Omega-3 fatty acids — Tier II

EPA and DHA have human experimental evidence relevant to muscle physiology. Controlled studies in older adults have demonstrated increased anabolic responsiveness or favorable effects on muscle mass and function under certain conditions. Their GLP-1 companion role, however, remains unproven.

A reasonable development hypothesis would test whether approximately 1.5–3 g/day combined EPA+DHA modifies muscle preservation, inflammatory phenotype or functional recovery during major incretin-induced weight loss. But there are practical problems.

High-dose oils increase formulation volume, can produce reflux or gastrointestinal symptoms and may therefore be poorly suited to some patients already experiencing dyspepsia. Consequently, omega-3 should probably be an optional module rather than part of the core formulation.

Urolithin A — Tier III, high scientific interest

Urolithin A is an attractive mitochondrial-health candidate.

A randomized clinical trial in older adults found improvements in measures of muscle endurance and mitochondrial biomarkers following oral supplementation. Its relevance to GLP-1 treatment remains entirely translational. Nevertheless, older patients undergoing substantial weight loss represent precisely the population in whom reduced muscular reserve and mitochondrial quality could become clinically relevant.

Urolithin A therefore deserves consideration as a second-generation muscle-resilience module, not inclusion in the first core product. A reasonable research program would initially test approximately the ranges already studied in human trials rather than invent a new dosing paradigm.

Evidence anchor: Liu et al. (2022).

Candidate	Current status in ICN	Development logic
Complete protein	Core	Adequate intake and high-quality indispensable amino-acid delivery remain foundational.
Essential amino acids	High-priority translational	Potential advantage when tolerated gastric volume is severely constrained.
Creatine monohydrate	Direct research priority	Strong external evidence for resistance-training support and now direct GLP-1-specific clinical investigation.
HMB	Selective	Most rational in older, frail or low-muscle-reserve phenotypes; not a universal add-on.
EPA/DHA	Optional translational	Potential muscle/metabolic relevance but GI tolerance and incremental GLP-1 benefit remain uncertain.
Urolithin A	Exploratory	Human mitochondrial/endurance signal outside GLP-1; dedicated incretin evidence absent.

CHAPTER 03

Nutritional Adequacy, Gastrointestinal Tolerance and Hydration

The therapeutic diet must remain nutritionally dense while respecting nausea, early satiety, altered transit and the safety consequences of persistent vomiting or volume depletion.

Micronutrients: precision supplementation, not the return of the megadose multivitamin

Recent observational data justify concern about nutritional adequacy during incretin therapy.

In the large retrospective analysis by Butsch and colleagues, newly diagnosed nutritional deficiencies were recorded in 12.7% of patients within six months and 22.4% within twelve months after GLP-1RA initiation. Vitamin D deficiency was the most frequently documented abnormality. The cohort consisted predominantly of patients with diabetes and relied on diagnostic claims, so it cannot establish either true population prevalence or direct drug causality.

This is exactly why the solution should not be an indiscriminate “GLP-1 mega-multivitamin”. Micronutrient management should be risk-stratified.

Particular attention may reasonably be directed toward protein status and dietary adequacy, vitamin D, iron status, vitamin B12, folate and calcium intake, with magnesium, zinc, thiamine and other nutrients assessed according to diet, symptoms, comorbidity and clinical circumstances. Persistent vomiting or profound dietary restriction deserves particular attention because thiamine depletion can become clinically important far more rapidly than many consumers realize.

Iron provides a good example of why precision matters.

An iron-containing supplement may be valuable in confirmed deficiency. Given unnecessarily, it can produce gastrointestinal adverse effects and complicate an already difficult GI tolerance profile. The correct principle is therefore:

Supplement demonstrated or highly plausible insufficiency — not the drug name itself.

Evidence anchor: Butsch et al. (2025); Urbina et al. (2026).

Vitamin D — Tier IV unless deficiency or insufficiency exists

Vitamin D has legitimate physiological relevance for normal muscle and bone function, but "GLP-1 therapy" is not itself an indication for high-dose vitamin D. The scientifically defensible model is:

screen → identify inadequate intake or status → correct appropriately.

The same principle applies throughout micronutrient development. A premium product containing very high vitamin D simply because it targets GLP-1 users would be inferior to a moderate baseline formulation plus a precision-correction pathway.

Calcium — Tier IV

Major weight loss and aging can create legitimate concern regarding skeletal integrity. But **calcium** should primarily close the gap between habitual intake and physiological requirements. It should not be automatically pushed to pharmacological levels.

A randomized trial combining a GLP-1 receptor agonist with exercise showed that exercise materially influenced bone-health outcomes during weight loss, illustrating why mechanical loading cannot be replaced by a calcium tablet. Bone preservation should therefore combine:

adequate dietary protein, adequate calcium, vitamin D sufficiency and weight-bearing/resistance exercise.

Thiamine — Tier IV but clinically important

Thiamine is unlikely to become a glamorous commercial ingredient.

It may nevertheless be one of the micronutrients that deserves the greatest clinical vigilance in individuals with prolonged vomiting, extremely low food intake or severe dietary restriction. The underlying rationale is straightforward: body stores are limited, and clinically significant deficiency can develop more rapidly than deficiencies of many other micronutrients. For this reason, prolonged vomiting should trigger clinical assessment, not merely consumer self-treatment with a generic multivitamin.

Vitamin B12 and folate — Tier IV

Reduced dietary diversity can make **B12** and **folate** adequacy relevant, particularly where pre-existing dietary restriction, metformin exposure, vegetarian/vegan diets or other risk factors coexist. Again, the correct model is not maximal dosing. It is risk stratification and biochemical confirmation where appropriate.

Iron — Tier IV and deliberately excluded from the universal formula

Iron illustrates why a universal GLP-1 multivitamin is poor clinical design. Iron deficiency can contribute to fatigue and hair shedding. But supplemental iron can also worsen nausea, abdominal discomfort or constipation and should not be indiscriminately given to individuals without deficiency. Therefore:

the ICN core multinutrient should preferably contain no iron, or only a carefully justified amount.

Iron should exist as a separate precision-correction module after assessment of hemoglobin, ferritin and the broader iron phenotype where medically appropriate.

Zinc — Tier IV

Zinc adequacy is relevant to normal immune, skin and hair biology. But the therapeutic principle remains the same:

deficiency correction rather than pharmacological excess.

Chronic high zinc intake can also interfere with copper metabolism. That alone argues strongly against simplistic “hair-loss mega-formulas”.

Selenium — Tier IV

Selenium sits in an even narrower therapeutic window. Insufficiency can be clinically relevant. Excess intake can itself produce adverse effects including hair and nail abnormalities. A product marketed for GLP-1-associated hair loss that indiscriminately provides high selenium therefore risks doing precisely the opposite of what it claims to support.

Magnesium — phenotype-dependent Tier IV

Magnesium should not automatically be included at large doses in every companion product. Certain salts have osmotic gastrointestinal effects that may theoretically assist constipation but aggravate diarrhea. Renal function also matters. This is another argument for abandoning the universal “GLP-1 supplement” in favor of phenotype-adapted modules.

Gastrointestinal tolerance is not a secondary issue; it is a formulation endpoint

Nausea, vomiting, diarrhea, constipation, abdominal discomfort, reflux and dyspepsia are established adverse effects of GLP-1 and dual-incretin treatment. For semaglutide 2.4 mg, the US prescribing information reports nausea, diarrhea, vomiting and constipation among the most common adverse reactions. Tirzepatide likewise

produces substantially more gastrointestinal adverse events than placebo, particularly during dose escalation. These effects have direct nutritional consequences.

Vomiting and diarrhea can cause volume depletion; semaglutide prescribing information specifically warns about acute kidney injury associated with dehydration secondary to gastrointestinal adverse reactions. But this creates another important development lesson:

there should probably be no single gastrointestinal GLP-1 formulation.

A patient with constipation and a patient with diarrhea have opposite nutritional requirements. A high-fiber magnesium-containing product marketed indiscriminately to both would be pharmacologically naïve.

The logical architecture is symptom-adaptive:

The last line matters most.

Severe abdominal pain, persistent vomiting, inability to maintain hydration, suspected pancreatitis, gallbladder disease, significant renal impairment or clinically relevant hypoglycemia must not be repackaged as consumer supplement opportunities.

Evidence anchor: Gorgojo-Martínez et al. (2023); FDA (2026); Eli Lilly (2026).

Hydration deserves its own product-development category

Hydration is often discussed as if “drink more water” were sufficient. It may not be.cReduced food intake also reduces the water ordinarily obtained from food. Nausea may reduce voluntary drinking; while vomiting and diarrhea increase fluid and electrolyte loss. Contemporary nutritional reviews commonly recommend active attention to hydration during GLP-1 therapy.

This creates a legitimate formulation space for low-volume, low-osmolality hydration systems. However, conventional sports drinks are not automatically ideal. Excess sugar, strong flavors, excessive sweetness, polyols or unnecessary electrolyte loading can undermine tolerance or be inappropriate for particular patients. Nor should universal sodium or potassium supplementation be recommended to people with hypertension, heart failure or renal disease. The useful innovation is therefore not “more electrolytes”. It is clinically intelligent hydration matched to symptom and patient phenotype.

Evidence anchor: FDA (2026); Eli Lilly (2026).

Psyllium — Tier II for the constipation phenotype

Psyllium has randomized clinical evidence for increasing stool water, improving stool consistency and improving constipation. Trials have commonly evaluated approximately 5 g twice daily, although dose and tolerance should be individualized. Its relevance to incretin therapy is obvious because constipation is a recognized

adverse event. However, formulation requires care. Large rapidly ingested fibre loads increase gastric volume and may be poorly tolerated in patients experiencing marked early satiety or nausea.

Consequently, an ICN fiber system should be:

titrated, hydrated adequately and offered separately from the anabolic core.

This is not a trivial formulation detail. It may determine compliance.

Partially hydrolyzed guar gum — Tier II/III

PHGG is attractive because it can provide soluble fiber with different technological and sensory characteristics from psyllium. Human randomized data in constipation show some benefit, although findings have not been uniformly positive. Rather than combining multiple fibers into an untestable proprietary blend, development should compare **psyllium versus PHGG versus placebo in incretin-associated constipation**.

The outcome should include bowel frequency, Bristol stool form, bloating, treatment adherence and impact on GLP-1 persistence. That would generate commercially meaningful evidence.

Hydration-electrolyte systems — Tier I physiological priority

Hydration is a special category because it is neither a conventional supplement problem nor merely a lifestyle issue. Current semaglutide prescribing information documents frequent nausea, vomiting and diarrhea and warns about kidney injury associated with gastrointestinal adverse reactions and dehydration.

Tirzepatide trials similarly show nausea, diarrhea, vomiting and constipation substantially more frequently than placebo, particularly during dose escalation.

This creates a legitimate need for hydration support. But the development mistake would be to simply repackage a high-sugar sports drink. The appropriate formulation should emphasize **low sensory burden, moderate electrolyte content, absence of unnecessary polyols, limited caloric load and high gastrointestinal tolerability**.

A consumer hydration-support product must also be clearly distinguished from medical oral-rehydration therapy for clinically significant dehydration.

Evidence anchor: FDA (2026); Eli Lilly (2026).

What should not become part of the category

Scientific credibility will depend as much on what the industry refuses to sell as on what it develops. There is currently no persuasive rationale for adding stimulants, thermogenic “fat burners” or aggressive appetite suppressants to already highly

effective incretin therapy. Likewise, routine digestive-enzyme cocktails, indiscriminate high-dose iron, megadose fat-soluble vitamins, high-dose magnesium products regardless of bowel phenotype or poorly substantiated “detoxification” ingredients do not address the core physiology.

Nor should probiotics be marketed as universal solutions for GLP-1-associated gastrointestinal effects until strain-specific and indication-specific evidence exists. The purpose of companion nutrition is not to amplify anorexia. It is to make a biologically successful weight reduction nutritionally and functionally safer.

Clinical state	Nutrition priority	Formulation direction
Early satiety / nausea	Minimize gastric burden	Small-volume, low-fat, highly digestible nutrition.
Vomiting / fluid loss	Maintain hydration	Appropriate fluid-electrolyte replacement; persistent symptoms require medical assessment.
Constipation	Progressive stool hydration and fibre	Titrated soluble fibre with adequate fluid, selected by tolerance.
Diarrhoea	Avoid osmotic excess	Low-polyol, cautious magnesium exposure, fluid replacement.
Reflux / dyspepsia	Reduce meal burden	Smaller portions, lower-fat systems, individualized timing.
Severe or persistent symptoms	Medical evaluation	Not a supplement problem.

CHAPTER 04

The Hidden Physiology of Rapid Pharmacological Weight Loss

Hair, skin, bone, oral health, fatigue, sleep and reproductive safety illustrate why companion care must distinguish drug effects from the physiology of rapid weight loss and reduced intake.

Beyond muscle: the second layer of incretin companion care

The first clinical challenge created by high-efficacy incretin therapy is relatively visible: patients lose substantial amounts of weight, energy intake declines, gastrointestinal tolerance may become limiting, and preservation of muscle and nutritional adequacy becomes important.

A second layer is less obvious.

Rapid and sustained changes in body mass, dietary intake, adipose distribution, gastrointestinal physiology and eating behavior can interact with tissues and physiological systems far removed from the conventional obesity-treatment conversation.

1. Hair follicles.
2. Skin and connective tissue.
3. Bone.
4. The oral cavity.
5. Sleep.
6. Reproductive physiology.
7. Perceived energy and fatigue.
8. The gastrointestinal microbiome.

And, eventually, the biological transition that occurs if pharmacological treatment is reduced or discontinued.

These should not be treated as an arbitrary catalogue of “GLP-1 side effects”. In many cases the drug itself cannot be separated cleanly from the effects of substantial weight loss, reduced energy intake, pre-existing obesity, metabolic improvement, nutritional insufficiency or treatment-associated gastrointestinal symptoms. That distinction is fundamental.

The emerging field of Incretin Companion Nutrition (ICN) should therefore address not merely adverse events but a broader concept:

- **Physiological adaptation to high-efficacy pharmacological weight loss**

This creates a second-generation research question:

What physiological vulnerabilities emerge when the rate and magnitude of weight reduction exceed the patient's capacity to nutritionally, structurally and behaviorally adapt?

We propose that this mismatch be termed:

- **Adaptive Reserve Gap**

The Adaptive Reserve Gap (ARG) describes the theoretical difference between the speed of pharmacologically induced physiological change and the individual's ability to preserve nutritional, structural and functional homeostasis. This is a proposed research construct, not an established clinical diagnosis. It extends the concept of nutritional compression introduced earlier. Nutritional compression describes what enters the patient. Adaptive reserve describes how successfully the patient accommodates the resulting biological change.

Hair loss: the signal can no longer be dismissed

Hair shedding associated with modern incretin treatment has moved beyond anecdote.

Current US prescribing information for tirzepatide lists hair loss among common adverse reactions. Across pooled weight-management trials, hair loss occurred in approximately 4–5% of tirzepatide-treated participants versus 1% with placebo and was considerably more frequent among women; the prescribing information explicitly states that reported hair-loss events were associated with weight reduction.

Current semaglutide prescribing information likewise reports hair loss more frequently with treatment than placebo. More importantly, observational dermatological research is beginning to characterize the signal. Retrospective database studies have identified associations between semaglutide or tirzepatide treatment and new hair-loss diagnoses, including telogen effluvium and androgenetic alopecia patterns.

But the causal chain remains unresolved. Several mechanisms may coexist:

- rapid weight reduction
- → physiological stress
- → altered follicular cycling
- and/or
- marked caloric restriction

- → inadequate protein or essential nutrients
- → impaired hair-matrix substrate availability
- and/or
- pre-existing androgenetic susceptibility

→ clinically visible shedding after loss of metabolic or nutritional reserve.

It is therefore scientifically premature to describe this simply as "**drug-induced alopecia**".

A considerable proportion may resemble weight-loss-associated telogen effluvium, although direct pharmacological effects on follicular physiology cannot yet be excluded.

This uncertainty creates an unusually strong research opportunity.

Evidence anchor: FDA (2026); Eli Lilly (2026); Burke et al. (2025); Gupta et al. (2026).

The Hair Integrity Program should begin with diagnosis, not biotin

The obvious commercial reaction would be:

- **GLP-1 Hair Formula**

containing biotin, zinc, selenium, collagen and miscellaneous botanical extracts.

That would be scientifically weak. The correct sequence is:

phenotype → identify substrate deficiency or trigger → intervene → measure regrowth.

A prospective ICN hair protocol should characterize:

a) percentage body-weight loss;
b) velocity of weight loss;
c) daily protein intake;
d) menstrual status where relevant;
e) iron status when clinically justified;
f) thyroid function when indicated;
g) vitamin B12 and folate risk;
h) zinc exposure/status where appropriate;
i) medication history;
j) androgenetic alopecia phenotype;
k) preceding illness;
l) gastrointestinal intolerance;
m) duration and pattern of shedding.

The key research question should be:

Is hair shedding predicted more strongly by drug exposure, magnitude of weight loss, rate of weight loss, protein insufficiency or pre-existing follicular vulnerability?

That study could transform product development.

Hair-support formulation: a precision architecture

The first-generation nutritional intervention should therefore be deliberately conservative.

- Foundation
- Adequate complete protein

The hair follicle does not have priority over vital tissues when energy and protein availability are constrained. Protein sufficiency should therefore precede specialized nutricosmetic intervention.

- Conditional modules
- Iron

Only where deficiency or inadequate iron stores are demonstrated or clinically suspected.

- Zinc

Only when nutritional exposure is inadequate or deficiency is plausible.

- Vitamin B12 and folate

According to dietary and biochemical phenotype.

- Vitamin D

Correct insufficiency where present, rather than treating vitamin D as a hair-growth drug.

- Experimental layer

Potential second-generation candidates could include sulfur amino-acid strategies, selected collagen-derived peptides or other hair-specific nutritional matrices.

But they should be tested prospectively rather than hidden within a 20-ingredient mixture. Biotin deserves particular restraint.

Deficiency can affect hair, but high-dose biotin is not a scientifically convincing universal response to incretin-associated hair shedding and may interfere with certain laboratory immunoassays. The guiding principle should be: **do not supplement the symptom. Identify and correct the limiting biological factor**.

Skin changes: distinguish tissue loss from skin biology

Popular terminology such as “Ozempic face” is scientifically imprecise. Rapid or substantial reduction in facial adipose tissue changes:

1) facial volume;
2) soft-tissue support;
3) contour;
4) visibility of wrinkles;
5) apparent laxity.

No nutritional supplement can reconstruct lost facial adipose volume. That distinction must be explicit. However, loss of volume and skin quality are not identical questions. Dermal hydration, elasticity, extracellular-matrix turnover and connective-tissue characteristics can theoretically be modified without restoring lost adipose tissue.

That creates a legitimate nutricosmetic research domain.

Collagen deserves investigation — but the literature demands caution

Oral collagen peptides have generated numerous randomized trials.

Earlier meta-analyses reported improvements in hydration, elasticity and wrinkle-related outcomes. However, the more recent evidence is more nuanced. A 2025 meta-analysis found an overall favorable pooled signal but raised substantial concerns about methodological quality, heterogeneity and the influence of industry-funded studies. This is exactly the type of evidence that should encourage research rather than advertising certainty.

The appropriate conclusion is:

collagen peptides are sufficiently plausible to test in GLP-1-associated rapid weight loss, but they have not been demonstrated to prevent the morphological changes popularly called “Ozempic face”.

Furthermore:

> ***collagen must not replace complete protein.***

Its amino-acid profile does not provide a nutritionally complete substrate for skeletal-muscle protein synthesis. The muscle and dermal strategies must therefore remain distinct.

Evidence anchor: Myung & Park (2025); Pu et al. (2023).

Oral hyaluronate: an underexplored nutricosmetic candidate

Oral sodium hyaluronate has also generated controlled human data suggesting possible improvements in skin hydration and other biophysical parameters.

The evidence remains considerably smaller than for conventional nutritional ingredients and is entirely non-GLP-1-specific. That makes hyaluronate a Tier III translational candidate rather than an established component. A rational experimental dermal formulation could therefore investigate: The important innovation is not the ingredients themselves. It is testing them during documented rapid pharmacological weight loss.

Evidence anchor: Dolečková et al. (2026); Hsu et al. (2021).

Bone: the biological problem is more sophisticated than calcium deficiency

Substantial weight loss reduces mechanical loading. That alone can influence bone turnover and bone mineral density. In a randomized study following diet-induced weight loss, liraglutide treatment alone was associated with reductions in bone mineral density at clinically relevant sites, whereas combining GLP-1 therapy with exercise produced substantial weight loss while better preserving skeletal outcomes.

More recent semaglutide pilot data in older adults remain insufficient to define the long-term skeletal consequences conclusively, reinforcing the need for targeted investigation rather than categorical claims. This leads to an important principle:

Bone preservation is a mechano-nutritional problem.

Nutrition alone cannot reproduce skeletal loading.

Evidence anchor: Jensen et al. (2024a).

Bone Resilience should therefore be a program, not a supplement

A credible ICN bone program would combine:

- Mechanical stimulus
  1) Progressive resistance exercise.
  2) Weight-bearing activity where appropriate.

- Nutritional substrate
  1) Adequate protein.
  2) Adequate calcium intake.
  3) Vitamin D sufficiency.
  4) Clinical stratification

Particular attention to:

1) older adults;
2) postmenopausal women;
3) low baseline bone mineral density;
4) previous fragility fracture;
5) very rapid or substantial weight loss;
6) chronic corticosteroid exposure;
7) low habitual calcium/protein intake.

A universal “GLP-1 Bone Formula” would oversimplify the physiology. The innovation should instead be an ***integrated Bone Resilience Protocol***.

Gallbladder disease: a commercially unattractive but scientifically essential conclusion

GLP-1 receptor agonists have a reproducible association with gallbladder and biliary events. A large randomized-trial meta-analysis found increased risk, particularly in weight-loss indications, at higher doses and with longer treatment duration.

A more recent analysis of 55 randomized trials involving more than 100,000 participants likewise identified increased cholelithiasis risk relative to placebo. Current tirzepatide prescribing information reports cholecystitis and related gallbladder outcomes during obesity trials. This should not trigger development of an herbal “gallbladder detox”.

There is currently no credible nutritional supplement that can be represented as preventing GLP-1-related cholelithiasis. That negative conclusion belongs prominently in the ICN framework.

a. Appropriate response
b. recognition of risk;
c. identification of previous gallstone disease;
d. awareness of very rapid weight reduction;
e. education regarding relevant symptoms;

and medical evaluation when indicated. Some clinical situations may require pharmacological or surgical management. Those are outside companion nutrition.

Oral health may be one of the most overlooked GLP-1 companion categories

The oral cavity deserves substantially more attention. Emerging clinical literature describes possible oral manifestations among semaglutide users including:

- xerostomia;
- altered taste;
- halitosis;
- consequences of recurrent vomiting;

and possible enamel exposure to gastric acid.

A recent dental review specifically highlights xerostomia, halitosis, enamel erosion associated with vomiting and taste alterations as issues requiring clinical awareness. Earlier case reports described marked hyposalivation developing during semaglutide therapy. These findings remain preliminary. They do not establish that semaglutide universally causes salivary-gland dysfunction. But they identify an entirely legitimate companion-care opportunity.

Evidence anchor: Mawardi et al. (2023).

Why xerostomia matters

Saliva is not simply lubrication.

It contributes to:

- buffering;
- oral clearance;
- remineralization;
- antimicrobial defence;
- swallowing;
- speech;

and taste perception.

Persistent dry mouth can therefore become clinically relevant even if it receives far less attention than nausea or constipation. And unlike some speculative nutraceutical targets, xerostomia admits a direct functional-accessory approach. This may become one of the most elegant extensions of Incretin Companion Care beyond classical supplementation.

A second oral-health issue: vomiting and acid exposure

Repeated vomiting and gastroesophageal reflux can expose dental enamel to acid. Consequently, patients with significant vomiting should not merely be sold hydration powder. Their oral health may require attention as well. A comprehensive GLP-1 companion program could therefore integrate:

GI management + oral protection + dental surveillance.

That is a much more sophisticated proposition than conventional supplementation. Current semaglutide and tirzepatide labels continue to identify vomiting and gastroesophageal symptoms among important adverse reactions.

Taste and food perception: a surprisingly important formulation variable

Incretin pharmacology affects more than hunger. Food preference, reward and sensory perception may change. Human research has reported associations between incretin-based therapy and altered taste perception and appetite regulation, while a semaglutide study in women with obesity was presented in 2024. These observations remain early and do not establish a universal sensory phenotype.

This has profound implications for formulation science. A flavor profile optimized for a conventional protein shake may become unacceptable during GLP-1 treatment. Highly sweet formulations may be particularly problematic for some patients. Strong aromas may aggravate nausea. Large flavor loads may reduce adherence.

We therefore propose another development concept:

- ***Sensory Compression***

A state in which the range and intensity of sensory stimuli that a patient comfortably accepts decreases during pharmacological appetite suppression or gastrointestinal intolerance. Again, this is a proposed research construct.

Evidence anchor: Kapan et al. (2025); Jensterle Sever et al. (2024).

Sensory-adaptive nutrition may become a competitive advantage

ICN formulations should be tested not only chemically but sensorially in patients receiving incretin therapy. Relevant development variables include:

- sweetness intensity;
- aroma intensity;
- viscosity;
- temperature;
- serving volume;
- aftertaste;

- fat sensation;
- carbonation;

and flavor persistence.

A technically perfect formulation that a patient abandons after three days has zero clinical value. Future GLP-1 nutrition trials should therefore measure:

- Effective Nutrient Delivery
- not simply

Nutrient Content.

The distinction is: **what the product contains versus what the patient repeatedly consumes**.

Fatigue: another symptom that should not automatically produce a stimulant product

Fatigue appears among common adverse reactions in current semaglutide and tirzepatide prescribing information. Yet “fatigue” is not a biochemical diagnosis.

Potential contributors include:

- excessive energy restriction;
- inadequate protein;
- dehydration;
- orthostatic symptoms;
- sleep disturbance;
- iron deficiency;
- vitamin B12 or folate deficiency;
- loss of physical conditioning;
- medication interaction;

and underlying disease.

The correct companion strategy therefore starts with phenotyping fatigue.

Evidence anchor: FDA (2026); Eli Lilly (2026).

The Energy Resilience Matrix

Rather than launching a caffeine-heavy “GLP-1 Energy Formula”, we propose a diagnostic architecture. This avoids one of the most dangerous supplement-industry reflexes: ***masking a symptom instead of identifying its cause.***

Sleep: incretin therapy can improve rather than merely disrupt physiology

Sleep provides a useful example of why the GLP-1 companion field must not be built around adverse effects alone. In the SURMOUNT-OSA randomized trials, tirzepatide substantially reduced obstructive sleep-apnea severity in adults with obesity, alongside reductions in body weight, hypoxic burden and inflammatory markers.

This means that for many patients with obesity-related sleep-disordered breathing, incretin therapy may improve an important underlying driver of poor sleep. It would therefore be scientifically inappropriate to assume that GLP-1 users universally require sleep supplements.

Instead, sleep belongs in the phenotyping architecture. Persistent fatigue or poor sleep despite substantial weight loss may warrant evaluation for residual obstructive sleep apnea, insomnia, restless legs, medication effects or other conditions. Not another bottle of melatonin.

Evidence anchor: Malhotra et al. (2024).

Cognition: the field received an important reality check in 2026

The hypothesis that GLP-1 receptor agonism might directly slow neurodegeneration generated considerable scientific interest. That hypothesis has now faced a major clinical test.

The large phase III EVOKE and EVOKE+ trials evaluated oral semaglutide in early symptomatic Alzheimer's disease. Semaglutide influenced several Alzheimer's-related biomarkers but did not slow cognitive and functional decline compared with placebo over the primary clinical evaluation period. This result is extremely important for companion-nutrition development.

It reminds us that: **biological plausibility and biomarker movement do not equal clinical benefit**.

The same evidentiary standard must be applied to nutraceuticals.

There should therefore be no first-generation “GLP-1 Brain Formula”

At present, the evidence does not justify a universal nootropic formulation specifically for incretin users. If patients experience cognitive complaints, the first investigation should consider:

- inadequate caloric intake;
- dehydration;
- sleep;
- iron/B12/folate status;

- hypoglycemia in susceptible patients;
- medication interactions;

and depression or other medical factors.

Only after these are addressed does experimental cognitive nutrition become intellectually defensible. This is another domain in which restraint strengthens rather than weakens the platform.

Reproductive physiology: clinically important and commercially dangerous

The relationship between obesity, weight loss and reproductive function is complex.

In women with PCOS and obesity, earlier GLP-1 studies have reported improvements in metabolic parameters and, in some settings, reproductive outcomes. A small, randomized pilot study combining liraglutide with metformin before IVF reported greater pregnancy rates than metformin alone, although the study was small and does not establish a general fertility indication.

In men with obesity-associated functional hypogonadism, a randomized study found that liraglutide-associated weight loss was accompanied by improvement in testosterone and reproductive-axis parameters.

More recent semaglutide data in obese men have also generated signals relating to sperm morphology and testosterone. But conflicting observational findings exist, including a database study reporting a higher incidence of erectile-dysfunction diagnoses among young men prescribed semaglutide for obesity. The field is therefore nowhere near ready for a simplistic “GLP-1 sexual health supplement”.

Pregnancy planning is a safety pathway, not a supplement category

This point is particularly important. Current US Wegovy prescribing information advises discontinuing semaglutide two months before a planned pregnancy.

Current tirzepatide prescribing information advises discontinuation when pregnancy is recognized. It also states that delayed gastric emptying may reduce the effectiveness of oral hormonal contraceptives and recommends switching to a non-oral method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose escalation. That is not a minor footnote.

Any sophisticated companion platform targeted partly at women of reproductive age must include contraception and pregnancy-planning education. This could become a clinically meaningful component of the digital companion system. It should not be buried beneath a fertility-marketing narrative.

Evidence anchor: FDA (2026); Eli Lilly (2026).

The reproductive companion pathway

A scientifically responsible system could distinguish:

- **Active treatment / pregnancy not desired**

Medication-specific contraception information and medical counselling where relevant.

- **Preconception transition**

Medical planning for withdrawal of the anti-obesity medication, stabilization of weight and nutritional adequacy.

- **Post-treatment conception planning**

Conventional evidence-based preconception nutrition rather than a proprietary “GLP-1 fertility booster”.

- **Male fertility concerns**

Clinical evaluation before nutritional intervention.

This may not generate the most glamorous product. It generates something more valuable: **trust and clinical legitimacy**.

A DELIBERATE NON-PRODUCT DECISION

Some real clinical needs should not become supplement opportunities. Gallbladder symptoms, persistent vomiting, unexplained severe fatigue, pregnancy planning and other safety-critical situations require medical pathways rather than additional consumer products.

CHAPTER 05

Microbiome and Emerging Translational Biology

The microbiome is scientifically attractive precisely because it is not yet sufficiently characterized to justify a generic “GLP-1 probiotic”. Discovery should precede product selection.

GlyNAC — Tier III, exploratory

Combined glycine and N-acetylcysteine supplementation have generated intriguing human data relating to glutathione metabolism, oxidative stress, mitochondrial biology and physical function in older adults. That evidence does not establish benefit during incretin treatment. GlyNAC should therefore remain outside any first commercial GLP-1 formula. Its appropriate position is within an exploratory translational program examining ***mitochondrial stress, oxidative balance, physical function and recovery during substantial weight reduction***.

This is exactly the type of compound that should be studied before being marketed.

Pasteurized *Akkermansia muciniphila* — Tier III and a microbiome research opportunity

The microbiome is almost certain to become commercially overexploited in the GLP-1 field. The correct response is not to avoid it entirely, but to impose a high evidentiary threshold. Pasteurized *Akkermansia muciniphila* has human randomized data in overweight/metabolic populations and remains under active clinical investigation.

What has not been demonstrated is that it prevents GLP-1 gastrointestinal adverse effects or improves tolerance to semaglutide or tirzepatide. Therefore, its most interesting research question is not:

“Can we put Akkermansia in a GLP-1 product?”

It is:

Does incretin therapy create a microbiome phenotype in which a defined next-generation microorganism or postbiotic modifies tolerance, metabolic adaptation or weight-maintenance physiology?

That would be a scientifically meaningful trial.

The microbiome: probably important, definitely overmarketed

GLP-1 biology and the intestinal microbiome interact conceptually at multiple levels:

- nutrient exposure;
- gastric emptying;
- bile-acid metabolism;
- intestinal transit;
- microbial metabolites;

and endogenous incretin signaling.

Animal models demonstrate substantial microbiome changes following semaglutide or tirzepatide treatment. For example, semaglutide altered microbial composition and intestinal-barrier markers in diet-induced obese mice. Human evidence is much thinner.

A small clinical study comparing metformin and liraglutide has reported systemic and microbiome changes, but the evidence base is nowhere near sufficient to specify an optimal "GLP-1 microbiome signature". Therefore: ***There is currently no scientific basis for a generic multi-strain probiotic labelled "for GLP-1 users***". This should be stated explicitly.

The microbiome opportunity is nevertheless enormous

The absence of evidence is precisely why the field is attractive for prospective investigation.

Instead of asking: **Which probiotic should we add?**

the appropriate questions are:

- Question 1

Does semaglutide or tirzepatide produce a reproducible microbiome trajectory independent of weight loss and dietary change?

- Question 2

Do patients who develop severe nausea, constipation or diarrhea have identifiable baseline microbial signatures?

- Question 3

Can microbiome composition predict treatment tolerance?

- Question 4

Does the microbiome predict weight regain after withdrawal?

- Question 5

Can a defined probiotic, next-generation microorganism, postbiotic or prebiotic modify a clinically relevant endpoint? Those questions could produce genuine intellectual property.

Microbiome trial architecture

A prospective ICN cohort should obtain stool samples at:

- baseline
- dose escalation
- active weight loss
- weight plateau
- and, where relevant,

post-treatment transition.

Simultaneously record:

- diet;
- protein;
- fiber;
- bowel frequency;
- Bristol stool type;
- nausea;
- vomiting;
- medication;
- weight-loss velocity;
- glucose phenotype;

antibiotic exposure.

Only after these data exist should specific microbiome interventions be selected. Otherwise the industry risks trying to manipulate an ecosystem it has not characterized.

Postbiotics may ultimately be more attractive than conventional probiotics

From a formulation perspective, postbiotics and defined microbial metabolites may eventually offer several advantages:

- greater formulation stability;
- reduced viability constraints;
- potentially more reproducible dosing;

easier combination with other nutritional matrices.

But that is a development hypothesis, not evidence of clinical superiority. A second-generation ICN program could therefore screen:

- defined postbiotics;
- selected microbial metabolites;
- specific prebiotic fibers;
- pasteurized next-generation organisms;

before committing to conventional probiotic cocktails.

RESEARCH DISCIPLINE

The appropriate sequence is **phenotype → mechanism → trial → product**. Reversing that sequence is likely to produce attractive labels but weak science.

CHAPTER 06

Maintenance and the Post-Incretin Transition

The nutritional problem changes when appetite suppression weakens. The treatment period should be used to build the physiological and behavioural infrastructure required for durable maintenance.

The most important neglected market may begin when the patient stops the drug

The post-incretin transition is potentially one of the largest unmet needs in the entire category.

The STEP 1 extension demonstrated that, during the year following withdrawal of semaglutide 2.4 mg, participants regained approximately two-thirds of the weight they had previously lost.

SURMOUNT-4 reached the same fundamental conclusion with tirzepatide: participants switched from tirzepatide to placebo regained substantial weight, whereas continued treatment maintained and extended weight reduction.

This does not mean every individual necessarily regains all lost weight. It demonstrates that loss of pharmacological appetite control creates a predictable maintenance challenge.

This changes the companion-nutrition business model

If the category is designed only for patients actively injecting semaglutide or tirzepatide, it misses half of the physiological problem. There are potentially three commercially and clinically distinct populations:

- **GLP-1 Initiation**

Manage tolerability and nutritional compression.

- **GLP-1 Active Loss**

Protect muscle, nutritional status and structural health.

- **GLP-1 Maintenance / Transition**

Protect the achieved body composition and manage the return of appetite.

The third population may ultimately be the most valuable.

Evidence anchor: Wilding et al. (2022); Aronne et al. (2024).

Exercise provides one of the strongest clues about post-treatment resilience

A randomized study combining liraglutide with supervised exercise produced an especially interesting finding after treatment cessation. One year after both interventions had ended, individuals who had previously received structured exercise regained substantially less weight than those who had received liraglutide without the exercise intervention. This suggests something fundamental.

The pharmacological period should not merely be used to lose weight.

It should be used to build the physiological and behavioural machinery required to maintain it.

This concept deserves a name:

- Therapeutic Exit Readiness

The degree to which the patient's nutritional, muscular and behavioural environment is prepared to maintain metabolic benefit if pharmacological intensity changes.

This is again a proposed construct.

Evidence anchor: Jensen et al. (2024b).

Companion nutrition should therefore begin preparing for discontinuation on day one

This changes the entire philosophy. The patient should not spend twelve months simply eating less because appetite is pharmacologically suppressed. That period is an opportunity to establish:

- protein-focused eating;
- higher dietary quality;
- resistance training;
- fiber adequacy;
- hydration habits;
- meal structure;
- self-monitoring;
- portion literacy;
- identification of hunger versus habit;

maintenance-compatible foods.

The treatment period becomes a metabolic learning window.

The goal is not merely:

lose weight while on GLP-1.

It becomes:

use the period of pharmacological appetite control to construct a body and behaviour capable of resisting regain.

Prototype J — ICN Transition Matrix

The maintenance product should be fundamentally different from the initiation product.

During initiation:

low volume is desirable.

During post-treatment transition:

satiety per calorie becomes much more important.

That potentially reverses the formulation architecture.

- Proposed Transition Matrix
- High-quality protein

to support muscle and satiety.

- Viscous soluble fiber

to increase food structure and gastrointestinal satiety.

- Whole-food-compatible texture

rather than exclusively liquid nutrition.

- Low energy density

to permit greater food volume after appetite returns.

- Minimal hyperpalatability

to avoid creating a highly reward-driven nutritional product.

This could be delivered through:

- bars;
- savory formats;
- structured meal components;
- powder-to-food systems;
- high-protein soups;

high-protein/high-fiber snacks.

The future GLP-1 market should therefore not be imagined exclusively as capsules and shakes.

The formulation should change as appetite changes

This yields one of the most important design principles of the entire framework:

- Phase-Reversed Formulation
- Early incretin therapy
- Maximum nutrition / minimum volume
- Active weight loss
- Maximum anabolic density / tolerated volume
- Weight maintenance
- Maximum nutrient density + satiety / controlled energy
- Post-treatment transition
- Maximum dietary structure / sustainable satiety

The ideal formulation at month two may therefore be almost the opposite of the ideal formulation after discontinuation. A static product cannot accommodate this physiology. A platform can.

The Maintenance Matrix should not try to imitate semaglutide

Another predictable commercial error would be to sell botanicals claiming to "naturally activate GLP-1" after medication discontinuation. That would generally be an inappropriate comparison. No conventional food supplement should be implied to reproduce the pharmacological exposure or clinical efficacy of semaglutide or tirzepatide. The nutritional objective is different.

It is to improve:

- satiety architecture
- dietary structure
- body-composition preservation
- behavioral durability

while the medical team determines whether pharmacotherapy should continue, change or stop.

A prospective Post-GLP-1 Transition Trial

This may ultimately be one of the most valuable studies in the program. Patients discontinuing or reducing incretin therapy could be randomized to:

- Standard lifestyle advice

- ICN Transition Program

comprising:

- individualized protein target;
- resistance-training program;
- structured soluble fiber;
- high-satiety meal architecture;
- digital appetite monitoring;
- weekly weight trajectory;

behavioral support.

Primary endpoint

Percentage of pharmacologically achieved weight loss maintained at 52 weeks.

Secondary endpoints

- fat-mass regain;
- lean-mass change;
- waist circumference;
- hunger ratings;
- food cravings;
- dietary protein;
- fiber intake;
- physical activity;
- quality of life;

cardiometabolic markers.

A successful trial of this type would create far more defensible intellectual property than another supplement formula.

A new endpoint: Retention of Therapeutic Benefit

We propose:

- RTB — Retention of Therapeutic Benefit

RTBweight = (weight loss retained after transition / maximum pharmacologically achieved weight loss) × 100.

If a patient loses 20 kg during therapy and retains 16 kg of that loss one year later:

RTB = 80%.

This is intentionally simple.

More sophisticated versions could incorporate:

- fat mass;
- waist circumference;
- HbA1c;
- blood pressure;

muscle strength.

The value of the concept is that post-treatment success should not be measured from baseline alone. It should measure how much of the therapeutic gain survives the transition.

Treatment phase	Dominant nutritional problem	Design principle
Initiation / escalation	Reduced tolerance and early satiety	Maximum useful nutrition with minimal gastric burden.
Active major loss	Muscle and nutrient preservation	High anabolic density, adequate protein, resistance training and phenotype-based support.
Plateau / optimization	Functional consolidation	Normalize food patterns, protein distribution, physical function and nutrient sufficiency.
Transition / withdrawal	Return of appetite	Higher food structure, protein + fiber, controlled energy density and behavioral durability.

CHAPTER 07

From Companion Nutrition to Companion Care

A clinically mature platform must combine nutrition with exercise, oral care, symptom phenotyping, digital support, laboratory referral and treatment-transition logic.

Why the category should be modular rather than “all-in-one”

The physiological state of a patient during week 2 of dose escalation is not the same as during month 12 of stable treatment. Neither are the needs of a 32-year-old physically active patient equivalent to those of a 74-year-old woman with low muscle mass.

A single universal product containing protein, fiber, creatine, magnesium, iron, collagen, probiotics and multiple vitamins may be commercially convenient while being physiologically irrational. We therefore propose a modular **Incretin Companion Nutrition** architecture.

This architecture also makes product development scientifically testable. Instead of asking whether an amorphous “GLP-1 supplement” works, trials can examine whether individual modules improve specific predefined outcomes.

A hierarchy of evidence for GLP-1 companion ingredients

A crucial methodological error would be to treat every plausible ingredient as equally validated. We propose four development tiers. This distinction prevents biological plausibility from being presented as clinical proof.

Twenty-four candidate components ranked for development

The purpose of this matrix is not to imply that all 24 ingredients belong in the same product. Quite the opposite. Putting all 24 together would destroy the scientific logic of the platform.

The decisive innovation: phenotype the GLP-1 patient

Patients should not be segmented merely by drug. They should be segmented by nutritional phenotype. We propose at least six clinically meaningful phenotypes: One patient may occupy several phenotypes simultaneously. That is why the platform should be algorithmic rather than product-centric.

Phase adaptation: needs change during treatment

The second major axis is time.

- **Phase 0 — Before treatment**

Establish baseline.

Body composition, dietary intake, muscle function, gastrointestinal history, renal function, relevant micronutrient risk and physical-activity capacity should be documented where clinically appropriate.

- **Phase 1 — Dose escalation**

The overriding problem is often tolerability.

The formulation priority becomes:

small volume, hydration, sufficient essential nutrients and avoidance of unnecessary gastric burden.

Current semaglutide and tirzepatide safety data show that gastrointestinal events occur particularly commonly during escalation.

- **Phase 2 — Active major weight loss**

Muscle preservation and nutrient density become dominant.

This is the logical period for:

protein optimization, resistance exercise, creatine research and body-composition monitoring.

- **Phase 3 — Weight plateau**

The objective changes from aggressive nutritional compression management toward functional optimization.

- **Phase 4 — Long-term maintenance**

The critical issue becomes preservation of healthy dietary behavior, physical function and the new body composition.

This longitudinal architecture may prove more clinically meaningful than selling the same supplement from day one indefinitely.

From supplementation to Companion Care

By this stage, it becomes clear that the field is larger than nutrition alone. We propose three related levels.

- **Level 1 — Incretin Companion Nutrition**

Protein, EAAs, creatine, micronutrients, fiber and hydration.

- **Level 2 — Incretin Companion Nutricosmetics**

Hair and dermal-support strategies.

- **Level 3 — Incretin Companion Care**

Nutrition plus:

- oral care;
- digital phenotyping;
- exercise;
- laboratory monitoring;
- reproductive safety;

treatment-transition support.

This broader architecture is scientifically stronger and commercially more defensible.

The complete emerging portfolio

The hidden commercial opportunity: accessories

The analysis also reveals a category that conventional supplement companies may overlook:

- GLP-1 Companion Accessories

Examples include:

- oral moisturizing sprays;
- xerostomia gels;
- structured hydration systems;
- small-volume nutrient delivery formats;
- protein dosing sachets;
- fiber-titration systems;
- portion tools;
- smart hydration bottles;
- digital symptom tracking;
- resistance-exercise guidance;

food-volume progression systems.

These products address real patient friction without inventing biochemical claims.

That can be both scientifically cleaner and regulatorily safer.

The digital layer becomes increasingly difficult to avoid

A static product cannot know whether a patient:

- has constipation or diarrhea;

- has lost 4% or 24% of body weight;
- consumes 35 g or 110 g of protein;
- is losing hair;
- is planning pregnancy;
- has severe nausea;

is approaching drug withdrawal.

A digital decision layer can.

A future ICN platform could calculate longitudinally:

- Nutritional Compression Risk
- Weight-Loss Velocity
- Muscle Vulnerability
- GI Phenotype
- Hair-Risk Phenotype
- Hydration Risk
- Transition Readiness

The system should not diagnose disease autonomously.

It would classify nutritional-support needs and trigger professional referral where appropriate.

A possible Incretin Companion Index

Ultimately, these dimensions could generate a research score:

- **Incretin Companion Needs Index — ICNI**

Potential domains:

This score does not currently exist.

It should be developed and validated rather than marketed as established medicine.

But possession of a validated ICNI would create something far more valuable than another proprietary powder.

It would create clinical infrastructure around the category.

The three phases of the incretin revolution

We can now describe the evolution of the field.

- **Incretin Revolution 1.0 — Weight Loss**

Question: How much weight can the drug remove?

Answered increasingly well.

- **Incretin Revolution 2.0 — Quality of Weight Loss**

Question: What tissue is lost and what functional capacity is preserved?

This phase is beginning now.

- **Incretin Revolution 3.0 — Quality of Adaptation**

Question: How well does the patient live, function and maintain the new physiology during and after treatment?

This is the territory of companion nutrition.

Final research hypothesis

The combined hypothesis arising from the first three parts can now be stated more completely:

High-efficacy incretin pharmacotherapy can create a mismatch between the speed of reduction in energy intake, food volume and body mass and the patient's ability to maintain nutritional, muscular, skeletal, dermal, oral and behavioral homeostasis. This mismatch—nutritional compression combined with an adaptive reserve gap—should be modifiable through phenotype-specific nutrition, exercise, functional accessories, clinical monitoring and phase-adapted interventions.

The hypothesis is falsifiable. Its components are measurable and virtually none have yet been tested as an integrated clinical program. That makes the research opportunity unusually large.

Phenotype	Dominant problem	Priority response
Anorectic-compression	Very low food volume	Low-volume EAA/protein architecture.
Muscle-vulnerability	Low reserve, older age, inactivity	Protein + resistance exercise + targeted muscle-resilience strategy.
GI-intolerance	Nausea, early satiety, reflux	Low-volume, low-fat, sensory-light formulations.
Constipation	Reduced bowel frequency / hard stool	Titrated soluble fiber + hydration.
Micronutrient-risk	Restricted diet or biochemical risk	Assessment-driven correction.
Dermal / hair	Shedding or skin-quality concern	Phenotype first; targeted, conservatively claimed support.
Transition	Appetite returning	Structured protein/fiber food + exercise + monitoring.

CHAPTER 08

Engineering the Product Platform — Publication Edition

Product engineering should solve defined physiological problems with the minimum necessary formulation burden. Potentially patent-sensitive preferred embodiments are deliberately generalized in this public edition.

From scientific framework to product engineering

The first three parts of this framework established a central proposition: high-efficacy incretin therapy creates nutritional and physiological demands that cannot be addressed rationally by placing the words “GLP-1 support” on a conventional multivitamin.

The next task is harder.

We must convert the physiology into products that can actually be manufactured, tolerated, clinically evaluated and legally communicated. That requires several disciplines simultaneously:

- clinical nutrition;
- food technology;
- amino-acid chemistry;
- gastrointestinal physiology;
- sensory science;
- nutraceutical formulation;
- regulatory affairs;
- clinical-trial methodology;
- consumer behavior;

cost engineering.

The resulting portfolio should not attempt to pharmacologically imitate semaglutide or tirzepatide. It should solve specific problems created by the therapeutic context. We therefore propose a twelve-product Incretin Companion Care engineering platform, deliberately divided between:

- core commercial products;

- phenotype-specific products;
- research-stage products;
- functional accessories;

post-treatment transition nutrition.

The formulations below are proposed R&D starting specifications, not final commercial recipes and not clinical prescriptions. Final composition must be validated through stability, microbiological, organoleptic, toxicological, regulatory and human-tolerance work.

Five rules should govern the entire portfolio

- **Rule 1 — Do not formulate around the drug name**

The formulation should address a physiological requirement:

- low protein intake

rather than:

semaglutide use.

This makes the science stronger and the regulatory position considerably more defensible.

- **Rule 2 — Minimize unnecessary ingredients**

The supplement industry frequently interprets product differentiation as ingredient accumulation.

For incretin users, that approach is particularly inappropriate.

Every additional ingredient may increase:

- gastric burden;
- taste intensity;
- osmotic load;
- pill burden;
- interaction potential;
- analytical complexity;
- stability problems;
- cost;

regulatory exposure.

The optimal ICN product should therefore contain the minimum ingredient architecture necessary to solve the defined problem.

- **Rule 3 — Optimize delivered nutrition, not label nutrition**

A formulation containing 30 g of protein has little value if the patient tolerates only half the serving.

Accordingly:

- Effective Nutrient Delivery =

nutrient concentration × fraction actually consumed × adherence.

This should become a product-development endpoint.

- **Rule 4 — Use EU-authorized claims where they genuinely fit**

The EU legal framework provides a surprisingly useful foundation for several parts of this platform.

Protein may carry the authorized claim that it contributes to the maintenance of muscle mass, subject to the applicable conditions. Creatine has an even more interesting, authorized claim: daily creatine consumption can enhance the effect of resistance training on muscle strength in adults over 55 years of age, provided the product supplies 3 g/day and the specified exercise conditions are met. Vitamin C, zinc, selenium, biotin, magnesium and several other micronutrients also have specific authorized physiological claims.

This provides sufficient regulatory communication territory without inventing claims such as:

- “prevents Ozempic muscle loss”
- or

“treats GLP-1 hair loss”.

- Rule 5 — Modules must not be stacked blindly

The platform is modular.

That does not mean that every patient should consume every module.

The cumulative intake of:

- vitamin D;
- zinc;
- selenium;
- calcium;
- magnesium;
- iron;
- other micronutrients

must be calculated across the complete nutritional programme.

EFSA's tolerable-upper-intake framework exists precisely because total chronic exposure—not merely the amount contained in one supplement—determines safety. The future ICN digital layer should therefore perform a cumulative nutrient-exposure check before recommending combinations.

Product-development cost index

Rather than inventing industrial prices without supplier quotations, we propose a COGS Intensity Index. This is deliberately not a €/unit estimate. Actual cost modelling should only follow:

- supplier RFQs;
- MOQ;
- assay;
- origin;
- packaging;
- manufacturing technology;
- batch size;

analytical specification.

The twelve-product architecture

The architecture intentionally includes products that are not supplements. That distinction is important. The biological problem created by incretin therapy cannot be solved entirely in capsule form.

Platform module	Problem addressed	Public-edition design principle	Priority
Anabolic MicroShot	Extreme nutritional compression	Complete EAA system engineered for very low-volume delivery; leucine-rich; explicitly not designed to increase satiety. Preferred ratios withheld.	Very high
Compact Protein	Inadequate daily protein	High-quality complete protein delivered in substantially less volume than a conventional shake; process/sensory parameters withheld.	Very high
Muscle Preserve 55+	Strength and muscle vulnerability	Creatine monohydrate integrated with resistance training; the commercial moat should be evidence and protocol, not ingredient novelty.	Very high
Muscle Reserve HMB	Frailty / low reserve	Selective research module for vulnerable phenotypes rather than universal inclusion.	Selective
Hydrate Clear	Reduced fluid tolerance	Low-sweetness, low-sensory-burden electrolyte system without unnecessary osmotic load.	High
Transit Duo	Constipation	Separate psyllium and PHGG pathways; titration by tolerance rather than a fibre cocktail.	High
Precision Base	Low micronutrient intake	Conservative micronutrient base; targeted correction rather than routine high-dose iron/minerals.	Medium-high

Platform module	Problem addressed	Public-edition design principle	Priority
Bone Resilience	Bone-risk phenotype	Exercise-led bone protocol supported by adequate protein, calcium and vitamin D status.	Selective
Dermal Matrix	Skin-quality concerns	Collagen/HA/vitamin-C research platform; no claim to restore lost facial adipose volume.	Medium-high
Hair Integrity	Hair shedding	Diagnostic/phenotype program before fixed supplementation; no universal high-dose biotin or iron.	High research value
Oral Hydration System	Xerostomia / oral discomfort	Mucoadhesive or lubricating oral-care system; exact formulation withheld pending IP review.	High differentiation
Transition Matrix	Appetite return / maintenance	Structured high-protein/high-fiber food architecture with deliberate texture and controlled energy density; exact preferred embodiment withheld.	Strategically critical

Flagship logic after product engineering

After examining physiological need, scientific differentiation, regulatory feasibility, development cost and competitive defensibility, three products stand above the others.

- FLAGSHIP 1
- ICN ANABOLIC MICROSHOT
- Strategic role
- Initiation + active weight-loss phase
- Problem solved

Nutritional compression.

- Differentiator

Maximum essential-amino-acid delivery in minimum tolerated volume.

- Scientific moat

GLP-1-specific trial measuring:

- protein adequacy;
- amino-acid delivery;
- adherence;
- DXA;

muscle function.

- Commercial difficulty

Medium.

- Regulatory difficulty

Medium.

- Competitive differentiation
- VERY HIGH

There are countless protein shakes.

There are far fewer formulations genuinely engineered around anabolic density and gastric-volume restriction.

- FLAGSHIP 2
- ICN MUSCLE PRESERVE 55+
- Strategic role

Older / muscle-vulnerable incretin population.

- Formula
- 3 g creatine monohydrate/day
- Differentiator

Product + resistance-training protocol.

- Scientific moat

Prospective GLP-1 body-composition and strength study.

- Regulatory advantage

There is an authorized EU creatine/resistance-training muscle-strength claim specifically for adults over 55 under defined conditions.

- Manufacturing difficulty

Very low.

- COGS

Very low.

- Commercial margin potential

High.

- Strategic rating
- EXCEPTIONALLY ATTRACTIVE

The formula is easy to copy.

The clinical protocol, digital exercise system and GLP-1-specific data are not.

- FLAGSHIP 3
- ICN TRANSITION MATRIX
- Strategic role

Maintenance / pharmacological transition.

- Problem solved

Return of appetite and loss of dietary structure.

- Differentiator

Phase-reversed formulation:

- from nutrient density per milliliter
- to

satiety and nutrient density per calorie.

- Scientific moat

52-week post-treatment maintenance trial.

- Regulatory platform

High-protein and high-fibre positioning is readily interpretable under EU nutrition-claim rules when compositional thresholds are met.

- Commercial potential

Potentially larger than the active-treatment supplement category because long-term maintenance may extend for years.

- Strategic rating
- VERY HIGH

Phase-based commercial architecture

A patient should not encounter twelve products simultaneously. The retail architecture should instead be phase-based.

- **PHASE I — START**
- Weeks 0–8 approximately

Possible modules:

- Anabolic MicroShot
- Hydrate Clear
- Compact Protein

Optional:

- Transit Duo

Objective:

tolerate therapy while preventing severe nutritional compression.

- **PHASE II — PRESERVE**
- Active major weight loss

Possible modules:

- Compact Protein

- Anabolic MicroShot
- Muscle Preserve 55+ where appropriate
- Precision Base

Optional phenotype modules:

- Bone
- Transit
- Hair

Objective:

maximize fat-loss quality and preserve functional reserve.

- **PHASE III — OPTIMIZE**
- Plateau/stable treatment

Priorities shift toward:

- normal food;
- protein distribution;
- exercise progression;
- body composition;

nutrient sufficiency.

Supplement dependence should ideally decrease.

That is important.

A clinically serious company should not design its system to make patients dependent on unnecessary products forever.

- **PHASE IV — TRANSITION**

The architecture changes completely.

Core:

- Transition Matrix

plus:

- structured resistance exercise;
- dietary fiber;
- whole-food protein;
- appetite monitoring;

body-weight trajectory.

Objective:

retain therapeutic benefit.

Digital selection logic

The platform now requires an algorithm because a patient may simultaneously qualify for several modules. A first-generation decision tree could use approximately ten variables:

1. Age.
2. Weight-loss velocity.
3. Current protein intake.
4. Number of tolerated meals.
5. Nausea/early satiety.
6. Constipation/diarrhea.
7. Resistance-training frequency.
8. Muscle-risk phenotype.
9. Hair/skin complaints.
10. Planned medication continuation/reduction.

Stop rules: when the platform should refer rather than sell

A sophisticated companion system must know when not to sell another product.

Examples requiring medical assessment rather than escalation of supplementation include:

- persistent vomiting;
- inability to maintain hydration;
- severe or persistent abdominal pain;
- suspected gallbladder disease;
- symptomatic hypotension;
- significant hypoglycemia;
- progressive unexplained weakness;
- severe hair loss of uncertain cause;
- pregnancy or pregnancy planning;

clinically relevant renal dysfunction.

This boundary materially increases the credibility of the entire system.

PUBLICATION BOUNDARY

The exact EAA ratios, preferred serving volumes, osmolality/pH windows, oral-system polymer architecture, sensory thresholds and algorithmic cut-offs belong in a confidential development dossier until patentability and FTO work are completed.

CHAPTER 09

Clinical Development and Evidence Generation

In a crowded ingredient market, prospective human evidence may become more defensible than the formula itself. Trials should measure tissue selectivity, function, tolerance and long-term benefit retention.

The next competitive frontier should be evidence generation

The greatest commercial mistake the nutrition industry could now make would be to repeat the historical pattern of creating formulations first and searching for scientific justifications afterwards.

The GLP-1 category is important enough to reverse that sequence.

We propose that companion products be evaluated against domain-specific clinical endpoints.

For **muscle-preservation** products, weight alone is inadequate. Trials should include DXA or validated body-composition methods, appendicular lean mass where appropriate, handgrip strength, sit-to-stand performance and ideally objective resistance-training exposure.

For **nutritional products**, outcomes should include dietary protein adequacy, nutrient intake, selected biochemical markers, adherence and gastrointestinal tolerance.

For **hydration interventions**, appropriate endpoints include intake, orthostatic symptoms where relevant, fluid-loss events and treatment discontinuation due to GI symptoms.

For **nutricosmetic products**, subjective photographs alone are inadequate. Hair studies should consider standardized hair counts, trichoscopic endpoints or validated shedding scores, while skin studies require objective elasticity, hydration or structural measurements.

The intervention must also be evaluated against the rate of weight loss.

A patient who loses 25% of body weight and 5 kg of lean mass is physiologically different from a patient losing 8% of body weight and the same absolute lean mass.

Preservation efficiency should therefore become a key concept: ***lean tissue or functional capacity preserved per unit of fat mass lost***. This would be substantially more informative than reporting percentage weight loss alone.

Proposed trial: the first true Incretin Companion Nutrition study

A robust first-generation trial could randomize adults initiating semaglutide or tirzepatide into:

- ***standard guideline-based nutritional counselling***

guideline-based counselling + a modular companion-nutrition system.

The intervention should prioritize adequate high-quality protein, a small-volume anabolic formulation, creatine where clinically appropriate, individualized micronutrient correction, symptom-adaptive hydration/fiber support and structured progressive resistance training. Participants should be stratified by age, sex, baseline muscle status, obesity class and incretin therapy.

Primary endpoints should include change in fat mass, appendicular lean mass and muscle function.

Secondary endpoints should include protein adequacy, treatment persistence, GI tolerability, selected micronutrient status, quality of life and the proportion of total weight loss represented by fat versus lean tissue.

A dermatological sub-study could prospectively assess hair shedding and skin elasticity rather than relying on retrospective adverse-event reporting.

Such a study would answer a far more relevant question than whether a supplement raises a biochemical marker:

Can companion nutrition improve the quality of pharmacological weight loss?

That should become the defining clinical question of this field.

A new research metric: Quality of Weight Loss

Traditional obesity trials report:

body weight, BMI, waist circumference and percentage weight loss.

Those metrics are insufficient for companion-nutrition research.

We propose that future studies explicitly characterize Quality of Weight Loss (QWL).

A basic tissue-level measure could include:

- **Fat-Loss Selectivity Ratio**

FLSR = fat mass lost / appendicular lean mass lost.

The higher the ratio, the greater the tissue selectivity toward adipose loss.

However, even this remains incomplete because preservation of DXA lean mass does not guarantee preservation of function.

We therefore propose a broader experimental construct:

- **Quality of Weight Loss Composite — QWL-C**

A research composite incorporating:

fat mass reduction + appendicular lean-mass preservation + muscle-strength preservation + physical-function preservation + nutritional adequacy + treatment tolerability.

This is explicitly proposed as a research construct, not a validated clinical score. Its value would be conceptual.

The question would no longer be:

- *"Who lost the most weight?"*

but:

"Who lost the greatest proportion of pathological adipose tissue while preserving the greatest amount of physiological reserve?"

That is a substantially more sophisticated definition of therapeutic success.

The ICN-MAP master clinical program

Rather than performing one small trial for every ingredient, we propose a master protocol:

- **ICN-MAP**
- ***Incretin Companion Nutrition — Master Adaptive Platform***

The architecture would begin as a phenotype-stratified multi-domain randomized platform and could evolve adaptively once sufficient data existed.

- **Population**

Adults initiating semaglutide, tirzepatide or another high-efficacy incretin-based obesity therapy.

Important stratification variables:

age, sex, baseline BMI, diabetes status, baseline appendicular lean mass, baseline strength, medication, planned incretin treatment, dietary protein intake and weight-loss velocity.

Core muscle-preservation trial

A first 24–36 week four-arm factorial study could evaluate:

An alternative design could randomize creatine independently within the protein/exercise arms to isolate its incremental effect.

This question is timely because both LEAN-PREP and a dedicated creatine/GLP-1 pilot are now investigating related hypotheses.

Primary endpoints

The trial should avoid relying on DXA alone.

Primary co-endpoints could include:

- percentage change in appendicular lean mass
- and

change in lower-body strength or chair-rise performance.

DXA would remain valuable for total fat mass, lean mass and regional composition. Where feasible, MRI or D3-creatine dilution could add more specific information about skeletal muscle. Current registered GLP-1 research is already employing sophisticated approaches to muscle assessment, including D3-creatine methodology.

Secondary endpoints

The trial should capture the real patient experience.

Important secondary domains include:

protein intake achieved, product adherence, gastrointestinal symptom severity, treatment discontinuation, hydration events, fat mass, visceral adipose tissue, grip strength, gait speed, sit-to-stand performance, physical-activity data, quality of life and biochemical nutrient status.

A companion product that improves DXA lean mass but causes nausea and poor adherence is not clinically successful. Tolerability must be considered an efficacy variable.

Nested GI trial

Patients developing constipation could enter a second randomized domain:

psyllium versus PHGG versus diet/hydration protocol alone.

Outcomes:

stool frequency, Bristol stool score, abdominal bloating, need for rescue medication, patient-reported tolerance and incretin-treatment persistence.

This would generate a genuinely GLP-1-specific evidence base rather than extrapolating indefinitely from generic constipation research.

Nested dermal trial

Patients experiencing ≥10–15% body-weight reduction could be randomized to:

- **control**

collagen + hyaluronate + vitamin-C-supported dermal module.

Objective endpoints should include:

cutometry, corneometry, TEWL, high-frequency ultrasound for dermal density, standardized three-dimensional facial imaging and patient-reported skin quality.

The study should explicitly avoid claiming restoration of adipose volume.

Prospective hair-loss cohort

The hair program should initially be observational rather than supplement-driven.

Patients should undergo standardized assessment before significant weight loss and at approximately months 3, 6, 9 and 12.

Variables should include:

hair density, standardized photography, shedding assessment, dietary protein, weight-loss velocity, iron indices where appropriate, thyroid status where clinically indicated and selected micronutrients.

Only after identifying predictors should a randomized nutritional intervention be designed.

This sequence — phenotype first, formulation second — could produce substantially more valuable intellectual property than immediately launching an undifferentiated hair supplement.

Digital companion layer

There is another major opportunity. ICN need not consist only of powders and capsules. A digital layer could collect:

weight trajectory, estimated protein intake, number of meals, fluid intake, nausea, vomiting, constipation, diarrhea, resistance-training adherence, fatigue and patient-reported hair/skin changes.

An algorithm could then recommend which nutrition module is appropriate. This changes the business model from a conventional supplement company toward a precision companion-nutrition platform. The future competitive advantage may therefore lie less in owning a particular molecule than in owning:

the phenotype algorithm + formulation system + longitudinal clinical dataset.

Proposed first clinical study

The first proprietary human study should not test all products simultaneously.

It should generate the clearest possible commercial and scientific answer.

I would propose:

- ICN-PRESERVE-01
- Population

Adults initiating semaglutide or tirzepatide for obesity.

- Duration

24–36 weeks.

- Core intervention

Standard nutritional/exercise guidance.

standard guidance + MicroShot/Compact Protein algorithm + Muscle Preserve creatine module where allocated.

Primary outcomes

- appendicular lean mass;
- fat mass;

chair-rise performance or lower-body strength.

Secondary outcomes

- daily protein achieved;
- treatment adherence;
- nausea/fullness;
- product completion;
- weight-loss velocity;
- proportion of weight lost as fat;
- grip strength;

quality of life.

The scientific question becomes:

Can a low-volume anabolic companion strategy improve the quality of weight loss?

That is publishable.

And commercially meaningful.

Second clinical study

- ICN-TRANSITION-01

This could become even more strategically important.

- Population

Patients reducing or discontinuing high-efficacy incretin therapy.

- Intervention
- Standard follow-up

Transition Matrix + resistance exercise + structured protein/fiber diet + digital appetite monitoring.

- Duration

52 weeks.

Primary endpoint

- Retention of Therapeutic Benefit — RTB

RTB = (maximum weight loss retained / maximum weight loss achieved) × 100.

Secondary

- fat regain;
- lean mass;
- waist;
- hunger;
- cravings;
- strength;
- dietary quality;
- protein;

fiber.

If positive, this trial could define an almost completely new commercial category.

Third clinical program

- ICN-APPEARANCE

Not because appearance should dominate clinical treatment.

Because it strongly affects patient satisfaction and adherence.

Two sub-studies:

- Hair Integrity

Prospective longitudinal phenotyping.

- Dermal Resilience

Randomized Dermal Matrix study.

This would allow the company to speak about nutricosmetics using its own incretin-specific human evidence rather than generic collagen literature.

Program	Core question	Illustrative primary endpoints
ICN-PRESERVE	Can low-volume anabolic support improve the quality of pharmacological weight loss?	Appendicular lean mass + strength/function; fat mass as contextual endpoint.
GI nested trial	Which symptom-adapted fibre/hydration strategy maximizes benefit per unit of GI burden?	Bowel frequency, stool form, bloating, rescue therapy, persistence.
Dermal Resilience	Can a targeted dermal module modify objective skin quality during major weight loss?	Elasticity, hydration, TEWL, dermal imaging.
Hair Integrity cohort	What predicts shedding during incretin-associated weight loss?	Standardized density/shedding linked to weight velocity, protein and clinical variables.
ICN-TRANSITION	Can structured companion care preserve achieved benefit after dose reduction/withdrawal?	Retention of Therapeutic Benefit at 52 weeks; fat/lean regain and hunger as secondary outcomes.

CHAPTER 10

Regulatory Architecture and Safety Boundaries

The scientific program may be GLP-1-specific while consumer claims remain firmly within applicable food, supplement, cosmetic, device and medicinal-product boundaries.

Regulatory reality: the phrase “GLP-1 support” does not remove the food–medicine boundary

The regulatory implications deserve particular attention.

Within the European Union, food supplements remain foods under Directive 2002/46/EC, while nutrition and health claims in commercial communications are governed by Regulation (EC) No 1924/2006 and the EU Register of authorized claims. Claims such as the contribution of protein to the maintenance of muscle mass can be used when the relevant conditions are satisfied.

What manufacturers cannot safely assume is that evidence supporting a nutrient allows them to claim that a food supplement prevents GLP-1-induced sarcopenia, treats semaglutide-associated hair loss, prevents gallstones or manages medicinal adverse effects. Those are materially different claims.

The strongest commercial strategy may therefore be one in which the scientific program is explicitly GLP-1-specific while consumer-facing claims remain legally compliant nutrient-function claims. This apparently conservative distinction will probably prove important as regulatory scrutiny increases.

Evidence anchor: Directive 2002/46/EC; Regulation (EC) No 1924/2006; Regulation (EU) No 432/2012.

Regulatory architecture in Europe

The regulatory positioning must remain conservative even if the scientific program is ambitious. European food supplements remain within the food framework under Directive 2002/46/EC. Authorized health claims are governed separately, including Regulation (EU) No 432/2012.

This creates an important dual architecture.

- Scientific language

Research may legitimately evaluate:

- “lean-mass preservation during semaglutide therapy”
- or

“skin elasticity following major incretin-associated weight loss”.

- Commercial consumer claims

The finished food or supplement must remain within applicable authorized nutrition/health-claim law.

For example, where the conditions are fulfilled, EU legislation provides authorized claims concerning protein and maintenance of muscle mass and vitamin C and normal collagen formation. The commercial communication should therefore not casually become:

- “prevents Ozempic muscle loss”
- or

“treats Mounjaro hair loss”.

That would cross an entirely different regulatory boundary.

Regulatory discipline becomes an asset rather than a constraint

The platform should distinguish **three languages**.

- Medical research language

“Preservation of appendicular lean mass during semaglutide treatment.”

Appropriate in a clinical study.

- Nutritional-function language
- “Protein contributes to the maintenance of muscle mass.”

Potentially appropriate in EU food communication when statutory conditions are met.

- Prohibited or high-risk consumer language
- “Prevents muscle loss caused by Ozempic.”

Potential medicinal/adverse-effect claim.

The scientific program can be much more ambitious than consumer-facing claims.

That separation is essential.

Regulatory communication must focus on vitamin C, not invent a collagen claim

The authorized EU claim is ***Vitamin C contributes to normal collagen formation for the normal function of skin.***

This is very useful.

What should not appear is:

- “reverses Ozempic face”;
- “restores facial volume”;

“prevents GLP-1 skin ageing”.

The product cannot recreate adipose tissue that has been lost. The clinical trial should instead measure:

- hydration;
- elasticity;
- dermal density;
- TEWL;

standardized facial morphology.

- Technology issue

Collagen peptides can be formulated easily.

The challenge is delivering 5 g/day while maintaining:

- low sweetness;
- low odor;

low flavor persistence.

This is much easier than the EAA MicroShot and therefore technically low risk.

The ingredient cost, particularly high-quality specific collagen peptides and branded HA, creates the larger COGS burden.

- Priority
- MEDIUM-HIGH

Commercially attractive. Scientifically useful if supported by an incretin-specific trial.

Regulatory classification requires special care

An oral-cavity product can fall within the EU cosmetic framework depending on its intended purpose; Regulation (EC) No 1223/2009 expressly encompasses products applied to teeth or oral mucosa within the cosmetic definition.

However, if the intended purpose and claims move toward treatment or management of a pathological condition, medical-device or medicinal-product questions may arise. Accordingly, classification must be decided before claims, packaging and clinical strategy are finalized, not afterwards.

- Priority
- HIGH STRATEGIC DIFFERENTIATION

This product demonstrates that Incretin Companion Care is broader than dietary supplementation.

Regulatory advantages

A formulation delivering 25 g protein within approximately 200 kcal would derive roughly half its energy from protein and would therefore comfortably exceed the EU high-protein threshold of 20% of energy, assuming the final product remains within those specifications.

A product containing 8 g fiber per 200 kcal would provide 4 g fiber/100 kcal and would therefore exceed the EU high-fiber criterion of 3 g/100 kcal.

This allows extremely powerful but legally conventional communication:

- HIGH PROTEIN
- HIGH FIBRE

Protein contributes to maintenance of muscle mass. No reference to drug substitution is needed.

Regulatory architecture for Spain and the EU

Food supplements remain governed at EU level by Directive 2002/46/EC and associated food-law requirements, while claims fall under Regulation (EC) No 1924/2006 and the authorized-claims framework.

Spain applies its national complement framework through Real Decreto 1487/2009 and requires communication of market placement; AESAN's control program states that notification is made before or simultaneously with placing a food supplement on the Spanish market.

This matters because product architecture should be regulatory-led from the first laboratory prototype. A formula that cannot be positioned legally is not a finished innovation.

Novel-food screen

Every non-conventional ingredient should pass a novel-food screen before development proceeds.

Two examples illustrate why.

- Sodium hyaluronate

Fermentation-derived sodium hyaluronate has been assessed as not novel in food supplements in the Commission consultation process.

- Pasteurized *Akkermansia muciniphila*

This is an authorized novel food, with specific conditions of use that have subsequently been amended, including a 2026 amendment.

Authorization as a novel food does not, however, automatically create an authorized health claim. This distinction is central.

Why *Akkermansia* is deliberately absent from the first twelve SKUs

It would look fashionable. That is precisely why it should not be included yet. The microbiome research program should first determine whether there is:

- a baseline responder phenotype;
- a constipation phenotype;
- a nausea phenotype;
- a post-treatment-regain phenotype

that is actually modified by a defined microbiome intervention.

Only then should the ingredient become a product.

The correct sequence is:

Phenotype → Mechanism → Trial → Product.

not:

Interesting ingredient → Marketing story.

Scientific research language	Potential compliant food-function language*	High-risk / inappropriate consumer language
Preservation of lean mass during incretin therapy	Protein contributes to the maintenance of muscle mass.	Prevents GLP-1-induced sarcopenia.
Skin elasticity during rapid pharmacological weight loss	Vitamin C contributes to normal collagen formation for normal skin function.	Reverses “Ozempic face”.
Strength during resistance training	EU-authorized creatine claim may be available for adults >55 under specified conditions.	Antidote to muscle loss caused by semaglutide.
Hair shedding phenotyping	Authorized nutrient-function claims where compositional conditions are met.	Treats tirzepatide alopecia.

*Illustrative only. Final wording, product classification, conditions of use and national notification/market requirements must be verified for the exact product and territory.

CHAPTER 11

Competitive Landscape and Intellectual Property

The market is no longer empty. The opportunity is to protect narrower technical solutions, phase logic, evidence and data rather than obvious ingredients or generic “GLP-1 support”.

The category is no longer hypothetical

There is an important correction to make before proceeding further.

When the Incretin Companion Nutrition framework was developed in the previous sections, several opportunities appeared to represent relatively open innovation territory. That assessment must now be qualified.

By August 2026, the major food and specialized-nutrition groups are no longer merely observing the incretin revolution. They are actively building around it.

Nestlé has launched foods and nutritional products explicitly targeted at people receiving GLP-1-based weight-management therapy and is using nutritional science and artificial intelligence to identify further product opportunities. Its R&D organization describes proprietary whey-protein microgel technology backed by multiple patents.

Danone is moving specialized medical-nutrition technology into mainstream GLP-1-oriented food products. In June 2026, Danone described Oikos Fusion as a food companion for people on a GLP-1 weight-loss journey; the product contains 23 g protein and incorporates what the company calls a protected “acticin” muscle-preservation engine, supported according to Danone by 16 clinical trials.

Herbalife has already commercialized a product family under the explicit designation GLP-1 Nutrition Companion, combining protein, fiber and other nutritional products for people using weight-loss medication.

The Vitamin Shoppe and other supplement retailers are selling formulations explicitly positioned around GLP-1-associated muscle, bone and nutritional support.

The implication is unequivocal:

GLP-1 companion nutrition is no longer a white-space market.

But that does not mean that the scientifically rigorous version of the category has already been built. It means that the competitive problem has changed. The relevant question is no longer:

- ***"Can we create the category?"***

It is:

"Which part of the category can still be defined more precisely, clinically validated more convincingly and protected more intelligently than what already exists?"

That is a much harder question. It is also a much more valuable one.

Evidence anchor: Nestlé (2025); Danone (2026); Herbalife (2024); Reuters (2026).

A methodological warning: this is a landscape, not a legal FTO opinion

The analysis that follows is a preliminary patent and competitive landscape. It is not a formal freedom-to-operate opinion. A proper FTO analysis requires, at minimum:

- exact commercial formulation;
- manufacturing process;
- intended indications and claims;
- target territories;
- claim-by-claim construction;
- patent-family analysis;
- prosecution histories;
- legal-status verification in official registers;
- possible equivalents;
- licenses and assignments;

expiry or supplementary rights where applicable.

A further limitation is particularly important in a market moving this quickly. PCT applications are normally published only after approximately 18 months from the priority date. Consequently, patent applications filed during 2025 or 2026 may currently be invisible to competitors unless early publication has occurred.

Therefore:

absence from today's patent databases is not evidence that no application exists.

The closer an innovation is to the current GLP-1 boom, the more significant this blind period becomes. This should influence development strategy. We should behave as though additional unpublished competitor filings almost certainly exist.

Evidence anchor: WIPO PCT publication rules; jurisdiction-specific status must be verified.

Competitive map: the category is stratifying rapidly

A useful way to understand the market is to distinguish five emerging competitive models. These are not equivalent threats. The strategically most important competitors are Nestlé and Danone because they combine:

clinical science** + **formulation technology** + **industrial scale** + **regulatory capability** + **patents** + **consumer brands.

Nestlé: probably the broadest current competitor

Nestlé has constructed the most visible multi-layered response.

Its Vital Pursuit range was explicitly developed as food intended to accompany GLP-1 weight-loss medication use, emphasizing protein, portion size and nutritional density. Its Boost Pre-Meal Hunger Support takes a different approach. The product is a small protein shot designed to be consumed before meals and uses whey-protein microgel technology to influence endogenous GLP-1 release and satiety. Reuters reported that the shot contains 10 g whey protein, 45 kcal and 1 g sugar, and that its formulation is patent protected.

Nestlé itself states that its whey-protein microgel technology is associated with 11 patents within a much broader whey-protein patent portfolio. This point directly affects our proposed Anabolic MicroShot. A small-volume protein or amino-acid shot for GLP-1 users cannot be regarded as novel merely because it is small-volume or because it is a shot. That territory is already occupied conceptually. Our differentiation must therefore lie elsewhere.

Evidence anchor: Nestlé (2025).

The crucial distinction between Boost Pre-Meal and the proposed Anabolic MicroShot

Nestlé's product is fundamentally a pre-meal satiety technology. The proposed **ICN Anabolic MicroShot** should deliberately be the opposite. Its objective is not:

increase satiety.

Its objective is to deliver essential anabolic substrate despite excessive satiety. That distinction must permeate formulation, patent drafting, clinical program and marketing.

- Nestlé model

Pre-meal.

Whey microgels.

Endogenous GLP-1 stimulation.

Hunger management.

Satiety.

- Proposed ICN model

Between meals or nutrition window.

Free essential amino acids.

Minimal caloric load.

Minimal gastric volume.

No satiety-enhancing objective.

Correction of inadequate anabolic-substrate delivery.

That is a much more defensible innovation axis.

The invention is therefore not:

- “a GLP-1 protein shot.”

It may instead become ***a low-volume essential-amino-acid delivery system engineered for individuals whose pharmacologically induced reduction in tolerated food volume prevents achievement of a predefined anabolic nutritional threshol***d.

That is far narrower. But narrowness can be an advantage in patent strategy.

Nestlé has also entered our post-treatment territory

The most important recent finding concerns our Transition Matrix.

On 17 August 2026, Nestlé's Chief Technology Officer told Reuters that the company had patented proprietary ingredient combinations intended to reduce appetite among people experiencing increased hunger after discontinuing GLP-1 treatment. Nestlé also described work on micronutrient combinations intended to support muscle tissue and products addressing hydration, nutritional intake, skin, hair and nails.

This requires a direct correction to our earlier analysis. The broad concept ***“nutritional intervention for increased appetite after stopping GLP-1”*** is not available to us as an uncontested innovation territory.

Nestlé has publicly stated that it already has patent protection directed at this problem. The precise patent family has not been conclusively identified in this preliminary search, so no assertion should be made about the exact scope of those claims. But strategically, the warning is enough.

Evidence anchor: Reuters (2026).

The Transition Matrix must therefore be repositioned

The defensible Transition Matrix should not be built around a proprietary appetite-suppressing ingredient. That is both scientifically unnecessary and now IP-sensitive.

Instead, the innovation should focus on:

- Phase-reversed food architecture

During active incretin treatment:

- maximum nutrition / minimum tolerated volume

After pharmacological reduction:

- maximum satiety and dietary structure / controlled energy
- Physical food structure
  1. Chewing.
  2. Viscosity.
  3. Food volume.
  4. Protein matrix.
  5. Fiber architecture.
  6. Energy density.
  7. Eating duration.
- Behavioral integration
  1. Meal timing.
  2. Appetite tracking.
  3. Resistance exercise.
  4. Weight-trajectory monitoring.
  5. Clinical endpoint
  6. Retention of Therapeutic Benefit — RTB.

This creates distance from a simple:

- “ingredient that suppresses rebound hunger.”

A Transition Matrix may remain highly valuable. But its potential protectability lies in how the transition is managed, not in discovering that appetite may return after treatment.

Danone/Nutricia may be the most important muscle-nutrition IP competitor

Danone's position is particularly relevant because its specialized-nutrition division has decades of research on muscle preservation, aging, frailty and weight-loss nutrition. In June 2026, Danone stated publicly that Oikos Fusion:

- contains 23 g protein.

- is intended as a food companion during a GLP-1 weight-loss journey.
- incorporates a protected muscle-preservation platform, and

draws upon technology previously used in medical nutrition.

Danone's agreement to acquire Huel further extends its access to nutritionally complete consumer meal solutions, although as of 30 June 2026 that acquisition had not yet completed. This means that the combination:

high protein + convenient format + muscle preservation + GLP-1 positioning

is already commercially occupied. It cannot be our primary innovation thesis.

Evidence anchor: Danone (2026).

Nutricia's older patent portfolio is directly relevant

One particularly important family predates the GLP-1 boom by more than a decade. US9961932B2, assigned to Nutricia, is entitled: ***"Muscle preservation in overweight or obese adult during weight loss program."*** Its claims address overweight or obese adults aged at least 40 participating in a hypocaloric weight-loss program with resistance exercise and receiving a nutritional composition containing defined ranges of proteinaceous matter, whey protein, leucine and vitamin D.

The patent describes, among other embodiments:

- 45–55% proteinaceous matter;
- 50–95% whey within the protein fraction;
- added leucine;
- vitamin D;
- 50–300 kcal servings;

administration in conjunction with resistance exercise and hypocaloric dieting.

Google Patents presently lists the US right as active, but its own database explicitly warns that legal-status information is not a legal conclusion; formal FTO would therefore require verification in the relevant official registers.

Consequence for Compact Protein

- Our proposed Compact Protein— a concentrated whey isolate/hydrolysate system in a substantially reduced serving volume —sits close enough to pre-existing muscle-preservation nutritional concepts that we should not assume composition-level patentability.

The danger increases if we add:

- leucine;
- vitamin D;

- fiber;
- an older overweight population;
- resistance exercise;

explicit muscle-preservation language.

Several of those features already appear together in Nutricia's earlier patent.

The most sensible strategy is therefore:

- Commercial product

Compact Protein can still be an excellent product.

- Patent position

Do not attempt to protect simply:

- “whey protein for preserving muscle during weight loss.”

That field is mature.

Instead, investigate whether protectable novelty exists in:

- extreme protein concentration per tolerated volume;
- sensory properties;
- viscosity;
- osmolality;
- hydrolysis profile;
- consumption completion under incretin-associated early satiety;
- specific protein-delivery architecture;

process technology.

Essential-amino-acid IP is also more crowded than it appears

Free EAAs are old nutritional technology. High-leucine amino-acid systems are also well represented in prior art. One particularly relevant US patent family concerns compositions for muscle growth, repair and maintenance incorporating a defined EAA profile together with whey protein and creatine monohydrate.

US11241399B2 claims a method involving a specified EAA distribution, 30–50% whey protein, creatine monohydrate representing 6–10% of active components and exercise.

This is extremely important for our product architecture. It means that an apparently attractive all-in-one product containing EAAs + whey + creatine would enter an area where existing claims already deserve detailed examination.

Modularization is therefore not merely good clinical design

Our earlier decision to separate:

- **Anabolic MicroShot**

EAAs.

- **Compact Protein**

Complete whey protein.

- **Muscle Preserve**

Creatine.

may have an unexpected intellectual-property advantage.

The modular structure potentially avoids creating exactly the kind of combined composition already claimed in certain existing patent families. This is not a finding of non-infringement; it is a design-around hypothesis.

But it demonstrates an important principle: **clinical modularity and IP modularity may reinforce each othe**r. That should be preserved unless future claim-chart analysis gives a compelling reason to combine the modules.

The Anabolic MicroShot still has potential — but not through the amino acids alone

The EAA ingredients themselves are unlikely to create strong exclusivity. The stronger invention may lie in the engineering constraints. Potential parameters deserving experimental development include:

- total EAA load;
- leucine fraction;
- minimum complete indispensable-amino-acid profile;
- strictly constrained preparation volume;
- maximum energy content;
- maximum fat;
- maximum fiber;
- viscosity range;
- osmolality range;
- pH range;
- bitterness threshold;
- completion time;

- patient-selection criterion;
- inadequate baseline protein intake;
- pharmacologically reduced meal volume;

measurable increase in daily EAA target achievement.

This turns a commodity mixture into a defined delivery system.

The crucial patent question becomes:

Is there an unexpected technical or physiological effect associated with the combination of these parameters?

If the answer after experimentation is merely:

- ***"amino acids still work in less water,"*** the invention may be weak.

If instead we demonstrate that a specific composition and sensory architecture produces materially greater effective anabolic nutrient delivery than conventional protein or EAA formats in patients with pharmacologically reduced intake, the inventive-step argument becomes substantially stronger.

A measurable technical problem is more valuable than a marketing problem

Patent applications become stronger when they can articulate a technical problem that has been solved nowadays. For the **MicroShot**, the problem might be framed experimentally as:

Existing high-protein nutritional formulations require a volume, flavor intensity or gastric load that prevents complete ingestion by a defined proportion of incretin-treated subjects with early satiety.

The solution would then need objective evidence:

- smaller tolerated volume;
- higher completion;
- defined amino-acid delivery;
- equivalent or improved postprandial EAA exposure;
- superior adherence;
- reduced fullness;

acceptable osmolality and sensory burden.

That is more defensible than:

- "Consumers taking GLP-1 drugs need protein."

The latter is already obvious.

HMB: existing formulation IP must be respected

Abbott has a substantial history in HMB-containing specialized nutrition. US9241508B2, for example, claims particular shelf-stable nutritional emulsions containing:

- protein;
- carbohydrate;
- fat;
- approximately 0.1–10% calcium HMB;
- defined calcium-binding characteristics;

specified pH and long-term physical stability.

This does not mean that every HMB product infringes that patent. The claims are structurally specific, but it illustrates why an RTD product containing protein + calcium HMB should not be formulated casually.

A dry HMB sachet has a very different technical architecture from the particularly shelf-stable emulsion claims identified here. That may become a useful design-around direction, subject again to proper jurisdiction-specific FTO.

Abbott is an adjacent competitor even without explicit GLP-1 branding

Abbott should not currently be described, based on this screen, as having built the same explicit GLP-1 consumer ecosystem as Nestlé or Herbalife. But dismissing Abbott would be a mistake.

Its current nutrition portfolio includes high-protein products such as Ensure Max Protein, and the company possesses deep clinical and patent experience in protein, HMB, medical foods and muscle-health nutrition. This makes Abbott an adjacent high-capability competitor. In strategic terms: ***a company does not need to have launched a GLP-1 brand today to represent an IP threat tomorrow.***

Herbalife shows what happens when speed precedes clinical validation

Herbalife is instructive for a different reason.

It launched its GLP-1 Nutrition Companion in 2024, combining existing protein, fibre and nutritional products for users of GLP-1 and other weight-loss medicines. The company's own consumer information states that the GLP-1 Nutrition Companion has not been clinically evaluated in GLP-1 patients. This creates an important competitive distinction. A scientifically ambitious entrant should not attempt to beat Herbalife simply by reaching market with another bundle. It should beat that model through: **GLP-1-specific prospective evidence**. That becomes a competitive asset.

Evidence anchor: Herbalife (2024).

Evidence itself should be treated as proprietary infrastructure

Suppose two companies sell essentially similar products.

- Company A

25 g protein.

5 g fiber.

Generic claims.

- Company B

25 g protein.

5 g fiber.

Plus prospective data showing:

- treatment-phase-specific adherence;
- body-composition outcomes;
- GI tolerability;
- patient phenotyping;
- weight-loss velocity;
- strength outcomes;

transition durability.

Even where composition patents are weak, Company B possesses a much more defensible market position.

The core asset becomes:

composition** + **clinical protocol** + **data** + **algorithm** + **brand.

This matters particularly in nutrition, where individual ingredients are often impossible to monopolize.

Muscle Preserve 55+: commercially strong, patent-wise much weaker than initially assumed

Creatine monohydrate remains an excellent product opportunity. But its broad GLP-1 use is already entering the public domain. ClinicalTrials.gov currently lists a study specifically entitled Creatine Supplementation During GLP-1a Therapy, combining creatine with resistance training to examine preservation of muscle mass.

That public disclosure matters for novelty.

The broad concept:

- ***"give creatine to GLP-1 users to help preserve muscle"*** should therefore now be regarded as very difficult to monopolize.

This is a significant distinction between:

- commercial attractiveness
- and

patent attractiveness.

They are not the same.

Evidence anchor: ClinicalTrials.gov NCT07625202.

The appropriate IP strategy for creatine is therefore different

For Muscle Preserve 55+, the competitive moat should probably be:

- Trademark

Distinctive proprietary branding.

Clinical evidence

Own GLP-1-specific trial.

- Digital training system

Resistance-training progression.

- Data

Strength and body-composition trajectories.

- Professional protocol

Patient selection and monitoring.

- Possibly patentable narrower inventions

Only if experimentation reveals a genuinely new technical or therapeutic feature.

The product itself— 3 g creatine monohydrate —is deliberately simple.

Its simplicity is commercially attractive. It is precisely why it is difficult to monopolize through conventional composition claims.

Satiety is one of the most crowded nutritional patent territories

The post-GLP-1 field becomes even more challenging because nutritional satiety technologies long predate semaglutide.

Recent patent applications continue to develop sophisticated gastrointestinal delivery systems for satiety modulation. WO2024216228A2, for example, describes compositions designed to control release of satiety modulators across gastrointestinal regions, including proteins, lipids, carbohydrates and other nutritional components, with controlled-release architectures and potential effects on satiety hormones. Nestlé itself has a long history of whey-protein-micelle patents for satiety and related

nutritional uses; European litigation concerning such technology predates the current GLP-1 market.

Therefore, the Transition Matrix should not try to compete by claiming that protein and fiber increase satiety. That is far too old and too broad.

What may remain protectable in Transition

The promising territory lies in phase adaptation. The hypothesis is not merely:

- ***"a food helps appetite control."***

It is:

the optimal physical and nutritional architecture of food should deliberately reverse when pharmacologically induced early satiety diminishes.

This can generate more specific invention disclosures around:

- Treatment-phase trigger

Initiation of GLP-1 dose reduction or withdrawal.

- Food architecture

Defined protein-fiber-energy ratio.

- Texture

Solid or semi-solid rather than liquid.

- Eating kinetics

Minimum chewing or consumption time.

- Volume

Higher physical volume than active-treatment products.

- Energy density

Predetermined maximum.

- Behavioral program

Structured meal replacement or meal-component use.

- Outcome

Retention of previously achieved therapeutic benefit.

Whether this ultimately reaches the threshold of patentability is uncertain. But it is significantly stronger than a generic appetite-management claim.

A preliminary FTO/patentability matrix

The two questions must be separated.

- Freedom to operate

Can we commercialize the product without infringing another party's enforceable claims?

- Patentability

Can we obtain valid exclusive rights over our own invention?

A product can score well on one and badly on the other.

*Subject to jurisdiction-specific searching and final composition.

These are strategic screening assessments, not legal FTO conclusions.

The patent strategy should concentrate money where exclusivity is plausible

A common corporate error is to patent everything. That wastes money and creates weak patents. The twelve-product portfolio should instead be divided into:

- Patent aggressively
- Anabolic MicroShot

if experiments establish genuine technical differentiation.

- Transition architecture

if sufficiently specific novelty can be demonstrated.

- Certain oral-delivery systems

if formulation produces objectively improved residence time or lubrication.

- Processing technology

where compact protein, bitterness reduction or stability requires proprietary methods.

- Consider selective patent protection
- Dermal Matrix

only if a particular combination or GLP-1-specific effect proves non-obvious.

- HMB phenotype

only if a specific patient subgroup produces an unexpected response.

- Algorithm

only if technical character can be established.

- Do not waste patent resources on obvious formulations

Creatine 3 g.

Generic multivitamin.

Basic electrolyte powder.

Psyllium.

PHGG.

Conventional protein shake.

These products can still be commercially valuable.

They simply require other forms of protection.

Trade secrets may be more valuable than patents for certain formulations

Patent publication exchanges secrecy for legal exclusivity. That is worthwhile where the patent is likely to be:

- valid;
- broad enough;
- commercially meaningful;

detectable when infringed.

It is less attractive where a competitor can readily design around the claims. Certain areas may therefore be better protected as know-how:

- flavour masking;
- bitterness suppression;
- hydrolysate selection;
- processing sequence;
- agglomeration;
- dissolution behavior;
- sensory models;
- supplier specifications;
- stability parameters;
- patient-selection algorithms;

datasets.

A competitor can chemically analyze the final amino-acid composition. It may be much harder to reverse engineer: ***why patients tolerate it better***. That know-how may be more valuable than another narrow composition patent.

Europe offers an interesting route for nutritional therapeutic-use patents — but only in the right circumstances

European patent law requires careful separation between nutrition and therapy. Article 54(5) EPC can permit purpose-limited protection for a known substance or composition used in a specific therapeutic application.

Recent EPO case law is particularly relevant. In T 1396/23, concerning a Nestlé nutritional composition, the Board of Appeal held that a substance or composition producing a therapeutic effect when replacing an essential nutrient in a nutritional composition could qualify as a "substance or composition" within Article 54(5) EPC.

But this route is unavailable merely because nutrition produces a desirable physiological result. In T 815/22, the EPO held that use of an infant formula to promote a normal growth trajectory did not constitute therapeutic treatment and therefore did not qualify for Article 54(5) purpose-limited medical-use protection.

This distinction matters enormously.

What this means for our proposed inventions

Consider two claims.

- **Claim concept A**

"An EAA composition for increasing dietary protein adequacy in GLP-1 users."

This may be nutritional rather than therapeutic.

Article 54(5) may not provide the desired protection.

- **Claim concept B**

"An EAA composition for prevention or treatment of a defined clinically relevant muscle disorder in a specified patient group receiving incretin therapy."

Potentially therapeutic.

But then:

- novelty;
- inventive step;
- sufficiency;
- clinical plausibility;
- prior art

all become critical.

The patent strategy therefore cannot be separated from the clinical-development strategy.

Clinical trials should be designed partly with patentability in mind

This does not mean manipulating research to obtain patents.

It means identifying endpoints capable of demonstrating a real technical effect.

For example:

- Weak endpoint

- “Consumers liked the product.”
- Better

A predefined high proportion of participants consumed the complete compact dose.

- Stronger

“Compared with a conventional protein beverage, the formulation increased successful delivery of the predefined indispensable-amino-acid target without increasing nausea/fullness.”

- Stronger still

“Successful nutrient delivery translated into measurable preservation of function or clinically relevant nutritional status.”

Such evidence can support:

- scientific publication;
- market differentiation;
- regulatory substantiation;

inventive-step arguments.

The clinical program and the IP program should therefore be designed together from the beginning.

Patent before publication

This point becomes essential given the publication ambitions of the present work. Any genuinely protectable invention must be assessed before detailed public disclosure.

Public disclosure of exact:

- composition;
- ranges;
- process;
- algorithm;
- experimental effect

can destroy novelty in many patent systems.

The scientific article should therefore describe the category conceptually while withholding enabling detail for inventions that have not yet been filed.

This creates a practical sequence:

- 1

Identify invention.

- 2

Create confidential invention disclosure.

- 3

Run prior-art search.

- 4

Generate preliminary experimental support.

- 5

File priority application.

- 6

Only then publish enabling details. This is particularly urgent because competitors are filing in the same field.

Our earlier article already contains ideas — but not necessarily fatal enabling disclosure

The concepts developed in Parts I–IV include:

- Nutritional Compression;
- Anabolic Density;
- phase-adaptive nutrition;
- Transition Matrix;
- phenotype-specific modules;

proposed formulation ranges.

Before any external publication, those sections should be reviewed from an IP perspective. If they remain private working material, there is no external disclosure problem. But if they are published, presented at conferences, uploaded publicly or distributed without confidentiality, the patent implications change materially.

Therefore, the publication version and patent-development version should now diverge. The public paper should explain the scientific paradigm.

The confidential R&D dossier should contain:

- exact compositions;
- ranges;
- manufacturing conditions;
- comparative examples;
- preferred embodiments;

candidate claims.

The digital algorithm is not automatically patentable

The proposed ICN digital layer is commercially attractive, but patent law does not give exclusivity merely because a decision tree is implemented on a computer.

The EPO's 2026 Guidelines state that AI or machine-learning features contribute to patentability where they achieve a technical effect; mere assertion is insufficient. Likewise, a computer program must provide a further technical effect beyond normal computer operation to avoid exclusion as such. Therefore:

- "Ask the patient five questions and recommend a supplement"

is unlikely to be a strong European software patent concept by itself.

A more promising digital architecture

The patentable technical problem might instead involve integration of objectively measured data.

For example:

- DXA/body-composition data
- weight trajectory
- wearable-recorded resistance exercise
- fluid intake
- dietary protein
- GI symptom parameters
- → algorithm calculates nutrient-delivery architecture

→ modifies physical dosing or formulation recommendation.

Even here, patentability would depend on the precise technical contribution.

The EPO recognizes that information modelling can contribute to technical character where it is used to solve a specific technical problem and produces a technical effect. The design team should therefore work with patent counsel before building the software architecture.

Data may ultimately be more defensible than the algorithm

Algorithms can often be reproduced. High-quality longitudinal datasets are much harder to recreate. Imagine a dataset containing, for thousands of incretin-treated patients:

- medication;
- dose;
- dose-escalation phase;

- body weight;
- body composition;
- protein intake;
- resistance training;
- GI symptoms;
- hydration;
- hair shedding;
- skin measurements;
- nutritional products;
- treatment discontinuation;
- appetite return;

one-year weight maintenance.

That becomes a major research asset.

It could support:

- predictive models;
- product iteration;
- publications;
- clinical partnerships;
- personalized nutrition;

future ingredient discovery.

The long-term competitive moat may therefore be:

data density per treated patient.

Trademark strategy: do not try to own the category descriptor

The name GLP-1 Nutrition Companion is already in commercial use by Herbalife. Consequently, building a new platform around an almost identical expression would be strategically poor even before undertaking formal trademark clearance.

“Incretin Companion Nutrition” and **“Incretin Companion Care”** are better scientific expressions because they are broader than a single GLP-1 drug class. But they also describe the purpose of the products very directly. EUIPO guidance makes clear that signs directly describing the characteristics or purpose of goods or services may be refused registration for descriptiveness or lack of distinctive character.

Therefore:

- Scientific/category designation
- Incretin Companion Nutrition

- Incretin Companion Care

Excellent.

Primary proprietary trademark

Probably not.

The correct naming architecture

We should separate three levels.

- Level A — Scientific category
- Incretin Companion Nutrition

Used in publications, conferences and scientific positioning.

It explains the field.

- Level B — Proprietary platform

A coined, distinctive master mark.

It should not literally describe:

- GLP-1;
- weight loss;
- protein;
- muscle;

nutrition.

Its job is to identify commercial origin.

A formal trademark clearance should precede public selection.

- Level C — Functional descriptors

Under the distinctive master brand:

- Anabolic
- Muscle 55+
- Hydrate
- Transit
- Dermal
- Transition

These need not carry the burden of exclusivity alone.

The master brand does.

The scientific terminology may nevertheless have substantial strategic value

Not every valuable term needs to become a monopoly.

If the academic literature begins using:

- Nutritional Compression
- Adaptive Reserve Gap
- Anabolic Density
- Quality of Weight Loss
- Therapeutic Exit Readiness
- Retention of Therapeutic Benefit

then the organization that originally defines and validates these constructs may acquire scientific authority, even without exclusive trademark rights.

This is analogous to building a school of thought rather than merely a brand. That can generate:

- citations;
- scientific recognition;
- clinical partnerships;
- conference invitations;
- licensing opportunities;

category leadership.

So the concepts should not necessarily be hidden. The formulations and enabling inventions should.

An emerging strategic term: Pharmacoadaptive Nutrition

The analysis points toward an even broader conceptual territory.

The physiological principle is not limited to GLP-1.

It could apply whenever pharmacotherapy significantly changes:

- appetite;
- food tolerance;
- nutrient requirement;
- metabolism;

body composition.

A broader scientific discipline could therefore be described provisionally as:

- **Pharmacoadaptive Nutrition**

meaning:

nutrition deliberately adapted to the physiological consequences and treatment phase of pharmacotherapy.

A preliminary web search did not reveal the expression as an established nutrition category, but that is not equivalent to trademark or patent clearance and should not be represented as proof of novelty. Its advantage is strategic.

“Incretin Companion Nutrition” describes the first application.

“Pharmacoadaptive Nutrition” could describe the larger scientific field.

Potential future applications include:

- incretin therapy;
- oncology;
- corticosteroid treatment;
- bariatric pharmacotherapy;
- certain neurological treatments;

medicines affecting appetite or gastrointestinal physiology.

This deserves independent linguistic, trademark and academic novelty assessment before adoption.

The category could therefore have a hierarchical scientific structure

- Pharmacoadaptive Nutrition

The broad discipline.

- Incretin Companion Nutrition

Application to incretin-based obesity pharmacotherapy.

- Initiation Nutrition

Tolerability and nutritional compression.

- Active-Loss Nutrition

Muscle and nutrient preservation.

- Maintenance Nutrition

Function and dietary quality.

- Transition Nutrition

Therapeutic exit and benefit retention.

This architecture is more durable than a platform tied specifically to semaglutide.

Which elements may constitute genuine white space?

After considering the current competitive and patent landscape, several earlier ideas must be downgraded.

No longer credible as major white space

- “high-protein food for GLP-1 users”;
- “protein to preserve muscle during weight loss”;
- “small protein shot”;
- “fiber for GLP-1 constipation”;
- “vitamins for GLP-1 users”;
- “collagen for appearance during weight loss”;
- “nutrition after stopping GLP-1” in the broadest sense;

“creatine during GLP-1 therapy” as a simple concept.

Those concepts already have either substantial prior art, active commercial execution or explicit research disclosure.

The stronger remaining spaces

- White Space A — Nutritional Compression as a quantified phenotype

Not merely “reduced appetite”.

A measurable state in which tolerated food volume and nutrient delivery become insufficient relative to defined requirements.

Potentially linked to:

- screening;
- intervention threshold;
- dosing;

product selection.

- White Space B — Anabolic Density

Not “high protein”.

Instead:

anabolic substrate successfully delivered per tolerated gastric volume.

That metric may create a genuinely differentiated formulation and clinical-development paradigm.

- White Space C — Non-satiety-enhancing EAA microdelivery

This is particularly important.

Most weight-management products try to increase satiety.

Our product is intended to overcome the nutritional consequences of excessive satiety without counteracting the therapeutic objective.

That inversion is conceptually strong.

- White Space D — Phase-Reversed Formulation

The same patient receives fundamentally different food architecture at:

- dose escalation;
- active loss;
- plateau;

withdrawal.

The platform, not an isolated product, becomes the invention.

- White Space E — Therapeutic Exit Readiness

Preparing the patient for potential medication reduction while treatment is still active.

This goes beyond an appetite suppressant after discontinuation.

- White Space F — Quality-of-Weight-Loss endpoints

Especially integrated outcomes linking:

- fat loss;
- lean-tissue preservation;
- muscle function;
- nutritional adequacy;

tolerability.

- White Space G — Effective Nutrient Delivery

Distinguishing labelled nutrient content from the quantity actually consumed and tolerated.

This is particularly relevant to severe early satiety.

- White Space H — GLP-1-specific sensory engineering

Sweetness.

Aroma.

Viscosity.

Serving temperature.

Volume.

Aftertaste.

These have received far less commercial attention than macronutrient composition.

- White Space I — Oral companion care

Xerostomia and oral-tolerance products remain much less developed than protein or fibre categories.

A genuinely optimized mucoadhesive or oral-hydration system may offer stronger formulation IP than another micronutrient tablet.

The most promising patent family may therefore not protect a molecule

The strongest application could eventually protect a system.

Conceptually:

A phase-adaptive nutritional system comprising a first low-volume anabolic composition for administration during pharmacologically induced appetite suppression and a second higher-volume, high-protein/high-fiber food architecture for administration following reduction or discontinuation of said pharmacotherapy, selected according to predefined nutritional and physiological criteria.

That is only an invention concept. It is not a proposed legal claim, and its novelty and inventive step have not been established. But it demonstrates where the strategic value may reside in the relationship between products and not merely the products themselves.

A second possible invention family: the Anabolic Density platform

A confidential invention disclosure should investigate:

- Composition characteristics

Defined EAA profile.

Defined leucine fraction.

Defined maximum volume.

Defined energy ceiling.

Defined pH/osmolality.

Defined sensory constraints.

- Patient phenotype

Documented reduction in food volume or inability to reach a predefined protein/EAA threshold during incretin treatment.

- Administration

Defined timing independent of appetite-suppression enhancement.

- Technical effect

Greater percentage of target EAA dose successfully consumed.

- Physiological endpoint

Muscle-protein synthesis or longer-term functional preservation.

This is one of the first areas in which I would commission a professional novelty search.

A third possible patent family: oral companion technology

The oral-hydration accessory may appear commercially secondary. From an IP perspective, it could be more interesting than a protein shake. Possible technical innovation might involve:

- specific hyaluronate molecular-weight distribution;
- mucoadhesive polymer combination;
- lubrication persistence;
- pH buffering;
- low sensory intensity;
- oral residence time;

use pattern during pharmacotherapy-associated xerostomia.

Unlike creatine or whey protein, this could involve genuine formulation engineering. That is often where stronger patents arise.

The scientific publication itself can become defensive prior art

There is another strategic possibility. Not every concept should be patented. Some concepts may be deliberately published to prevent competitors from later claiming them broadly.

Once an enabling disclosure becomes prior art, later applicants may find it harder to obtain broad exclusive rights over the same concept. This is a classic defensive-publication strategy, but it must only be used after deciding what we want to patent ourselves, otherwise we can destroy our own rights.

The sequence matters:

patent what deserves exclusivity; publish what deserves freedom.

What should remain confidential now

Before the definitive article is published, I would temporarily remove or generalize:

- Exact preferred EAA ratios.
- Exact pH/osmolality targets.
- Precise sensory thresholds.
- Specific process conditions.

- Preferred hydrolysis degree.
- Detailed Transition Matrix texture architecture.
- Algorithm thresholds.
- Proprietary phenotype cut-offs.
- Experimental combinations not yet filed.

The paper can remain scientifically powerful without disclosing every preferred embodiment.

What should be published aggressively

Conversely, I would strongly consider establishing publicly:

- Nutritional Compression.
- Adaptive Reserve Gap.
- Quality of Weight Loss.
- Anabolic Density as a general scientific metric.
- Therapeutic Exit Readiness.
- Effective Nutrient Delivery.
- Phase-adaptive companion nutrition.
- Retention of Therapeutic Benefit.

Why? Because these concepts position the authors intellectually at the center of the category. The formulations can remain proprietary, but the scientific vocabulary should become ours through authorship and citation.

The competitive moat should have seven layers

The resulting protection architecture would be:

- Layer 1 — Scientific authorship

Define the discipline and terminology.

- Layer 2 — Patents

Only for genuinely novel technical solutions.

- Layer 3 — Trade secrets

Sensory, process, supplier and algorithmic know-how.

- Layer 4 — Trademarks

Distinctive master brand and product family.

- Layer 5 — Clinical evidence

Prospective human data.

- Layer 6 — Digital system

Phenotype and treatment-phase decision architecture.

- Layer 7 — Proprietary longitudinal data

The hardest asset to reproduce.

No single layer is sufficient. Together they can become formidable.

Development	Preliminary FTO concern	Patentability potential	Strategic implication
Anabolic MicroShot	Medium	Medium–high if technically narrowed	Priority professional novelty/FTO work.
Compact Protein	Medium–high	Low–medium	Differentiate through process, tolerability, evidence and brand.
Muscle Preserve 55+	Low–medium	Low for simple composition	Clinical evidence + protocol + data.
HMB Module	Medium	Low–medium	Keep modular; detailed FTO before final formulation.
Hydrate / Transit / Precision	Generally lower	Low	Commercial utility; limited patent budget.
Dermal Matrix	Medium	Low–medium	Clinical differentiation more important than broad composition claims.
Oral Hydration System	Medium	Medium if genuine delivery innovation exists	High-priority technical search.
Transition Matrix	Medium–high	Medium if phase architecture is novel	Priority IP investigation; avoid generic rebound-appetite claims.
Digital platform	Variable	Variable	Patentability depends on technical effect, not merely a decision tree.

These are strategic screening assessments derived from the source manuscript, not legal freedom-to-operate conclusions. Patent legal status, claim scope and jurisdiction must be verified by qualified counsel.

CHAPTER 12

R&D Strategy and Category Leadership

A smaller innovation-led organization cannot out-scale global nutrition groups. It can compete by defining the scientific infrastructure they have not yet standardized: phenotype, phase, delivery, endpoints and longitudinal evidence.

The scientific program itself becomes the competitive moat

The strongest asset in this market may not ultimately be a secret formulation. Most of the best first-generation ingredients are already known as protein, amino acids, creatine, fiber, micronutrients and collagen. The defensible innovation lies in determining **who needs which ingredient, at what phase of treatment, in what dose, in what tolerated format, and with what measurable clinical outcome.**

The resulting asset can include **proprietary formulations, phenotype algorithms, clinical protocols, datasets, tolerability profiles, predictive models and potentially patentable combinations or use architectures where novelty and inventive step can legitimately be demonstrated**.

That is substantially harder to copy than a label containing fifteen ingredients.

A proposed development sequence

This sequencing deliberately puts basic physiology before novelty. That is how the category retains credibility.

Development Wave I

The first industrial wave should contain only products capable of reaching market relatively quickly while generating meaningful clinical data.

- Wave I-A
- Anabolic MicroShot

Primary sensory and tolerance development.

- Wave I-B
- Muscle Preserve 55+

Fastest route to market.

- Wave I-C
- Compact Protein

Technologically straightforward.

- Wave I-D
- Hydrate Clear

Supportive ecosystem SKU.

- Wave I-E
- Transit Duo

Constipation-specific.

Development Wave II

- Dermal Matrix

Clinical differentiation required.

- Hair Integrity Program

Prospective cohort first.

- Oral Hydration System

Classification + dry-mouth trial.

- Bone Resilience

Selective distribution.

Development Wave III

- Transition Matrix

Although strategically a flagship, it requires more food-development work because texture, satiety, food architecture and long-term compliance matter. A successful Transition Matrix should probably become an entire food family, not simply a powder.

Product intellectual property

The individual ingredients themselves will often be difficult to monopolize.

Protein is known.

Creatine is known.

Psyllium is known.

Collagen is known.

The IP strategy should therefore focus on several layers.

- Layer 1 — Formulation

Examples:

very-low-volume complete EAA architecture optimized for incretin-associated nutritional compression.

- Layer 2 — Use architecture

Defined nutritional phenotype + defined intervention.

- Layer 3 — Phase architecture

Different formulation depending on treatment phase.

- Layer 4 — Digital algorithm

Patient data → module recommendation.

- Layer 5 — Clinical dataset

This may eventually be the strongest moat.

Thousands of patients could create longitudinal relationships between:

- medication;
- appetite;
- nutrition;
- gastrointestinal symptoms;
- body composition;
- hair;
- skin;
- exercise;
- discontinuation;

weight regain.

Competitors can buy creatine.

They cannot instantly buy that dataset.

Brand architecture

The parent category should remain scientifically neutral.

For example:

- ICN™ — Incretin Companion Nutrition
- or
- ICC™ — Incretin Companion Care

The individual products should then communicate the physiological objective rather than the medicine:

- ICN™ ANABOLIC

- ICN™ PROTEIN
- ICN™ MUSCLE 55+
- ICN™ HYDRATE
- ICN™ TRANSIT
- ICN™ PRECISION
- ICN™ BONE
- ICN™ DERMAL
- ICN™ HAIR
- ICN™ ORAL
- ICN™ TRANSITION

This avoids locking the platform to:

- Ozempic;
- Wegovy;
- Mounjaro;
- Zepbound;
- semaglutide;

tirzepatide.

That is strategically important because the pharmacology of obesity treatment is evolving rapidly.

Commercial positioning

The category should never be positioned as:

- **“Supplements to make GLP-1 work better.”**

That invites scientific and regulatory problems.

A much stronger proposition is:

Nutrition built for the physiology of modern weight loss.

Or scientifically:

Preserving nutritional and functional resilience during high-efficacy weight reduction.

That is broader, more durable and more defensible.

The most important commercial distinction

Conventional supplement logic asks:

What ingredients can we sell to GLP-1 users?

Our framework asks:

What physiological problem does the patient have at this exact phase, and what is the minimum intervention required to solve it?

Those are fundamentally different business models. The first produces a product catalogue. The second produces a clinical platform.

Final portfolio ranking

Competitive position of the three flagships after the patent review

The analysis changes our ranking slightly.

- 1. ANABOLIC MICROSHOT
- Commercial attractiveness
- ★★★★★
- Patent potential
- ★★★★☆
- Competitive crowding
- ★★★☆☆
- Recommendation

Accelerate.

But redesign explicitly around:

EAA microdelivery + nutritional compression + non-satiety objective + measurable effective nutrient delivery.

Do not imitate Nestlé's pre-meal model.

- 2. MUSCLE PRESERVE 55+
- Commercial attractiveness
- ★★★★★
- Patent potential
- ★☆☆☆☆ for basic formulation

Clinical value

- ★★★★★
- Recommendation

Launch conceptually, but do not waste resources trying to own creatine itself.

Build exclusivity through:

- brand;

- exercise protocol;
- dataset;
- clinical evidence;

professional ecosystem.

- 3. TRANSITION MATRIX
- Commercial attractiveness
- ★★★★★
- Patent potential
- ★★★☆☆
- Competitive risk
- ★★★★☆
- Recommendation

Continue, but pivot IP strategy immediately.

Do not position the invention as: ***appetite suppression after GLP-1 withdrawal***. Nestlé is already explicitly operating there. Instead protect:

phase-reversed structured nutrition + behavioral architecture + benefit-retention methodology.

A fourth product now deserves promotion

After this competitive analysis, one product moves upward:

- ORAL HYDRATION SYSTEM

Why? Because:

- the protein field is crowded;
- the muscle field is crowded;
- the satiety field is crowded;

generic micronutrients are crowded.

Oral companion care remains comparatively less obvious. It involves genuine formulation engineering, creates a non-supplement adjunct and has a measurable endpoint, and it expands the platform from nutrition to companion care.

I would therefore move Oral Hydration into the first patent-screening group alongside MicroShot and Transition Matrix.

Revised R&D/IP priority

Ninety-day intellectual-property program

The next step should be highly disciplined.

- Days 0–15 — Invention capture

Prepare confidential invention disclosures for:

- A. Anabolic Density / MicroShot
- B. Phase-Reversed Transition Matrix
- C. Oral Hydration System
- D. Phase-Adaptive ICC platform

Each disclosure should contain:

- technical problem;
- prior solution;
- proposed solution;
- preferred embodiment;
- alternatives;
- ranges;
- manufacturing method;
- expected effect;
- available data;

experimental plan.

- Days 15–30 — Professional patent search

Search:

- EPO/Espacenet
- WIPO/PATENTSCOPE
- USPTO
- relevant national families

using:

- claims;
- citations;
- assignee clusters;
- CPC/IPC classes;

semantic searching.

Keyword searching alone is insufficient.

- Days 30–45 — Claim-chart FTO

For each commercial prototype:

Ingredient.

Concentration.

Process.

Format.

Use.

Target population.

Jurisdiction.

Map against live independent claims.

- Days 45–60 — Design around

Where overlap exists:

change:

- composition;
- ratio;
- format;
- processing;
- administration;
- patient criterion;

product combination.

Do this before clinical trials freeze the formulation.

- Days 60–75 — Experimental substantiation

Generate data specifically supporting the unexpected technical effect.

For MicroShot:

- solubility;
- bitterness;
- osmolality;
- stability;
- tolerated volume;

completion rate.

For Oral:

- viscosity;

- mucoadhesion;
- residence time;

lubrication.

For Transition:

- texture;
- energy density;
- eating rate;

satiety kinetics.

- Days 75–90 — Priority filing

File the strongest inventions.

Then move toward:

- publication;
- conferences;

scientific dissemination.

Final strategic conclusion

The patent and competitive review changes the narrative in an important way. We are not first to discover that GLP-1 users need nutrition. Nestlé knows it. Danone knows it. Herbalife knows it. Abbott has much of the underlying muscle-nutrition technology. Retail supplement companies know it.

The first wave of competition is already underway; therefore the opportunity is not to race them on the obvious. We should not compete for:

- more protein;
- more vitamins;
- more fiber;
- another collagen powder;

another “GLP-1 friendly” label.

Those battles will become commoditized. The valuable territory lies one level deeper. It lies in understanding why the patient fails nutritionally at a particular treatment phase, and then engineering the smallest, most precise intervention required to correct that failure. That produces a fundamentally different competitive thesis.

The emerging defensible territory

The portfolio should therefore revolve around four scientific assets:

- Nutritional Compression

Who cannot eat enough?

- Anabolic Density

How much useful anabolic substrate can actually be delivered within the volume that patient can tolerate?

- Phase-Reversed Nutrition

How should food architecture change as pharmacological appetite suppression changes?

- Therapeutic Exit Readiness

How should the active treatment period prepare the patient for long-term physiological resilience?

These ideas connect:

- nutrition,
- food technology,
- exercise physiology,
- digital health,
- clinical medicine,

and treatment transition.

That integrated structure remains far less developed than the individual ingredient market.

The strategic objective should now be reformulated

The objective is no longer:

Create the best GLP-1 supplement.

Nor even:

Create the best GLP-1 supplement range.

It should become:

Build the first clinically validated, phase-adaptive nutritional and functional architecture designed around the changing physiology of high-efficacy pharmacological weight loss. That is significantly more difficult.

It requires:

- patents;
- know-how;
- trials;
- software;

- food technology;
- biomarkers;
- regulatory discipline;

longitudinal follow-up.

But precisely because it is difficult, it is harder to copy.

The competitive race is therefore a race for infrastructure

Nestlé can manufacture foods. Danone can translate medical nutrition into FMCG. Abbott can leverage decades of muscle-health science. Herbalife can mobilize a global distribution network.

A smaller innovation-driven organization cannot beat those groups by producing a larger protein shake. It can compete by creating the scientific infrastructure they have not yet standardized:

- phenotype definitions;
- treatment-phase rules;
- nutritional algorithms;
- validated endpoints;
- precise low-volume delivery;
- transition protocols;

longitudinal datasets.

The competitive moat is therefore not a single ingredient. It is a system for understanding the patient.

STRATEGIC PRINCIPLE

Do not attempt to own protein, creatine, fiber or collagen. Build the system that knows when, why, how and for whom each should be used—and generate the evidence that proves it.

CHAPTER 13

Pharmacoadaptive Nutrition: The Broader Discipline

Incretin Companion Care can be understood as the first major use case of a broader proposition: precision nutrition engineered around pharmacologically altered physiology.

The conceptual framework is now broader than GLP-1

An interesting consequence emerges. The physiology we are describing will not be restricted permanently to semaglutide and tirzepatide. Future obesity pharmacotherapy is moving toward:

- dual agonists;
- triple agonists;
- amylin combinations;
- next-generation incretin agents;

increasingly potent body-weight reduction.

As pharmacological efficacy increases, nutritional compression and adaptive-reserve problems may become more—not less—important. The platform should therefore avoid tying its scientific identity exclusively to a single molecule or trade name.

“Incretin Companion Nutrition” is strategically stronger than **“Ozempic nutrition”.**

A new principle: efficacy creates secondary nutritional responsibility

Historically, modestly effective weight-loss interventions created modest physiological perturbations. Highly effective therapies alter the equation.

A drug capable of facilitating 15%, 20% or greater weight reduction creates a responsibility to ask what accompanies that success. Not because the therapy is intrinsically harmful, but precisely because it is powerful.

The more effective adiposity reduction becomes, the more important it is to protect:

- muscle;
- bone;
- nutrient status;

- hydration;
- functional capacity;
- oral health;
- hair and skin integrity;
- reproductive safety;

behavioral durability.

This is not an argument against GLP-1 pharmacotherapy. It is an argument for completing the treatment ecosystem.

An emerging strategic term: Pharmacoadaptive Nutrition

The analysis points toward an even broader conceptual territory. The physiological principle is not limited to GLP-1. It could apply whenever pharmacotherapy significantly changes:

- appetite;
- food tolerance;
- nutrient requirement;
- metabolism;

body composition.

A broader scientific discipline could therefore be described provisionally as:

- Pharmacoadaptive Nutrition

meaning:

nutrition deliberately adapted to the physiological consequences and treatment phase of pharmacotherapy.

A preliminary web search did not reveal the expression as an established nutrition category, but that is not equivalent to trademark or patent clearance and should not be represented as proof of novelty. Its advantage is strategic.

“Incretin Companion Nutrition” describes the first application.

“Pharmacoadaptive Nutrition” could describe the larger scientific field.

Potential future applications include:

- incretin therapy;
- oncology;
- corticosteroid treatment;
- bariatric pharmacotherapy;
- certain neurological treatments;

medicines affecting appetite or gastrointestinal physiology.

This deserves independent linguistic, trademark and academic novelty assessment before adoption.

The category could therefore have a hierarchical scientific structure

- Pharmacoadaptive Nutrition

The broad discipline.

- Incretin Companion Nutrition

Application to incretin-based obesity pharmacotherapy.

- Initiation Nutrition

Tolerability and nutritional compression.

- Active-Loss Nutrition

Muscle and nutrient preservation.

- Maintenance Nutrition

Function and dietary quality.

- Transition Nutrition

Therapeutic exit and benefit retention.

This architecture is more durable than a platform tied specifically to semaglutide.

From Incretin Companion Nutrition to Pharmacoadaptive Nutrition

There is also a broader scientific consequence. The framework developed around incretin therapy may represent only the first example of a larger discipline:

- Pharmacoadaptive Nutrition

Nutrition designed not merely around disease, age or lifestyle, but around the predictable physiological perturbations generated by pharmacotherapy.

Within that discipline:

- Incretin Companion Nutrition

would become the first major use case.

This would transform the intellectual proposition from:

- “nutrition for people taking GLP-1 drugs”

into:

“Precision nutrition engineered around pharmacologically altered physiology.”

That is a much larger scientific idea.

And potentially a much more durable one.

Conclusion

The GLP-1 companion market is already being occupied. The scientific category, however, remains immature. Existing commercial approaches largely concentrate on recognizable nutritional components as protein, fiber, vitamins, muscle support, hydration and satiety.

The opportunity for the next generation is not to add more components, it is to create greater precision. The products must respond to:

which patient, at which treatment phase, with which physiological limitation, using which formulation architecture, at which tolerated dose, to produce which measurable outcome.

Patent strategy should follow exactly the same logic. Broad ingredient claims will frequently fail because the nutritional landscape is already mature. More defensible inventions may emerge from: ***specific phenotypes, delivery engineering, phase adaptation, technical formulation parameters, unexpected effects, clinical algorithms, and integrated systems***.

The fundamental strategic principle can therefore be stated very simply: Do not attempt to own protein, creatine, fibre or collagen. Own the system that knows when, why, how and for whom each of them should be used. That may be the true intellectual-property opportunity created by the incretin era. And it is considerably more difficult to commoditize than another supplement.

The term **Pharmacoadaptive Nutrition** is proposed here as a conceptual label, not as a claim of legally established novelty, trademark availability or exclusivity. Adjacent literatures already discuss nutritional pharmacology and nutrition–drug interactions; formal bibliographic, linguistic, trademark and patent clearance would be required before commercial adoption.

DEFINITION

Pharmacoadaptive Nutrition: nutrition deliberately adapted to predictable changes in appetite, food tolerance, nutrient delivery, metabolism, body composition or functional reserve produced by pharmacotherapy and by changes in the intensity of that pharmacotherapy.

CONCLUSION

A Discipline Worth Building

The value of the category will depend less on how many supplements appear on shelves than on whether companion care measurably improves the quality and durability of treatment outcomes.

The GLP-1 era has revealed a paradox. Successful pharmacological appetite control can make energy restriction easier while making adequate nutrient delivery, physical adaptation and long-term maintenance more demanding. The response should not be a reflexive stack of protein, vitamins, fibre, collagen and probiotics. It should be a phenotype- and phase-adapted system with explicit safety boundaries.

The strongest immediate priorities remain simple: adequate complete protein, resistance exercise, hydration, gastrointestinal tolerance and correction of genuine nutritional insufficiency. Innovation should be layered on those foundations only where it solves a measurable problem. Essential-amino-acid microdelivery, creatine-supported resistance training, selected HMB applications, oral-care accessories, targeted nutricosmetics and transition foods deserve different levels of evidence and different commercial treatment.

The long-term scientific opportunity is larger than any one product. A validated framework that links medication exposure, appetite, tolerated food volume, body composition, symptoms, exercise, nutrition and post-treatment maintenance could become infrastructure for modern obesity care. The defensible asset is therefore not the ingredient list. It is the combination of physiology, formulation, protocol, data and evidence.

FINAL PROPOSITION

The clinically meaningful winner will not be the company that places “GLP-1” on the greatest number of labels. It will be the organization that demonstrates—prospectively, quantitatively and reproducibly—that companion care can improve the quality of weight loss, the quality of physiological adaptation and the retention of therapeutic benefit.

GLOSSARY

Glossary of Research Constructs

These terms are proposed for scientific discussion and require validation before use as established clinical metrics.

Adaptive Reserve Gap (ARG)

Mismatch between the rate of pharmacologically induced physiological change and the individual's ability to preserve structural, nutritional and functional homeostasis.

Anabolic Density (AD)

Anabolic substrate successfully delivered per unit of tolerated gastric volume.

Effective Nutrient Delivery (END)

Practical nutrient exposure after accounting for dose completion and adherence rather than label content alone.

Incretin Companion Care (ICC)

Integrated nutrition, exercise, oral care, digital phenotyping, safety referral and transition support surrounding incretin therapy.

Incretin Companion Nutrition (ICN)

Nutritional interventions adapted to the physiological and practical constraints of incretin-based pharmacotherapy.

Nutritional Compression

Contraction of energy intake and tolerated food volume while essential nutrient requirements fall much less, or not proportionally.

Nutritional Compression Gap (NCG)

Proposed conceptual difference between contraction in intake and proportional change in essential nutrient requirements.

Quality of Weight Loss (QWL)

Extent to which excess adiposity is reduced while muscle, function, nutritional adequacy and broader physiological resilience are preserved.

Retention of Therapeutic Benefit (RTB)

Proportion of previously achieved treatment benefit retained after treatment intensity changes.

Sensory Compression

Proposed reduction in the range or intensity of sensory stimuli comfortably accepted during pharmacological appetite suppression or GI intolerance.

Therapeutic Exit Readiness (TER)

Preparedness to preserve physiological and behavioral gains if medication is reduced or discontinued.

Pharmacoadaptive Nutrition

Proposed broader discipline of nutrition adapted to the predictable physiological consequences and phases of pharmacotherapy.

APPENDIX A

Evidence Hierarchy

A simple evidence-tier system prevents plausible ingredients from being presented as clinically established GLP-1 interventions.

Tier	Definition	R&D implication
I — Incretin-priority	Direct GLP-1 relevance, formal clinical recommendation or active GLP-1-specific program.	Immediate clinical-development priority.
II — Strong translational	Human randomized evidence in calorie restriction, aging, sarcopenia or resistance training; insufficient direct incretin evidence.	Strong candidate for dedicated GLP-1 trials.
III — Emerging mechanistic	Human biological/functional signal with substantial uncertainty regarding incremental benefit during incretin therapy.	Exploratory module.
IV — Precision correction	Useful primarily when diet, phenotype or biochemical findings indicate need.	Assessment-driven; do not formulate universally.

APPENDIX B

Companion Care Portfolio

The portfolio is a modular ecosystem rather than a one-product-fits-all supplement stack.

Module	Primary target	Status
Anabolic MicroShot	Extreme nutritional compression	Flagship / priority R&D
Compact Protein	Protein inadequacy	Core
Muscle Preserve 55+	Strength/function vulnerability	Flagship evidence program
Muscle Reserve HMB	High-risk muscle phenotype	Selective
Hydrate Clear	Low fluid tolerance	Core support
Transit Duo	Constipation phenotype	High
Precision Base	Micronutrient-risk phenotype	Selective core
Bone Resilience	Skeletal vulnerability	Risk-stratified
Dermal Matrix	Skin-quality research	Research/commercial
Hair Integrity	Hair shedding	Diagnostic + precision pathway
Oral Hydration System	Xerostomia/oral discomfort	High differentiation
Transition Matrix	Appetite return / maintenance	Strategically critical
Microbiome Programme	GI/metabolic discovery	Second generation

APPENDIX C

Clinical Endpoints

The central methodological principle is to measure biological and functional outcomes rather than body weight alone.

Domain	Recommended endpoint family
Body composition	Fat mass, appendicular lean mass, regional composition; MRI or other methods where appropriate.
Function	Strength, chair-rise, gait or other validated physical-performance measures.
Nutrition	Protein adequacy, diet quality, selected biochemical markers, actual product completion.
GI tolerance	Nausea/fullness, bowel frequency, Bristol stool form, rescue medication, discontinuation.
Hydration	Intake, symptomatic volume depletion where relevant, clinically significant events.
Hair	Standardized photography, density/shedding or trichoscopic endpoints.
Skin	Elasticity, hydration, TEWL, structural imaging.
Transition	Weight/fat regain, appetite, strength and Retention of Therapeutic Benefit over long follow-up.

APPENDIX D

Public / Confidential IP Boundary

Scientific leadership benefits from publication but enabling detail should not be released before deciding what requires patent or trade-secret protection.

Publish openly	Keep confidential pending IP review
Scientific category definitions and clinical rationale.	Exact preferred composition ratios and ranges.
General concept of phase-adaptive companion care.	Preferred osmolality, pH, viscosity and sensory thresholds.
Quality-of-weight-loss and benefit-retention research questions.	Specific process steps, hydrolysis/agglomeration parameters and supplier specifications.
Evidence hierarchy and clinical endpoints.	Algorithmic cut-offs and patient-selection thresholds.
Negative claims: what should not be sold as a universal solution.	Preferred embodiments and comparative experimental data intended to support inventive step.

SEQUENCE

Identify invention → confidential disclosure → prior-art/FTO search → experimental substantiation → priority filing → publication of enabling detail. Patent what deserves exclusivity; publish what deserves freedom.

REFERENCES

References

Selected scientific sources supporting the principal clinical and translational propositions. References are consolidated from the source manuscript and updated with current 2026 guidance and studies.

Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. PMID: 38078870.

Butsch, W. S., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., et al. (2025). Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity Pillars, 15, 100186. https://doi.org/10.1016/j.obpill.2025.100186

Dobbie, L. J., Tolvanen, L., Alves, D., et al. (2026). Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(26)00122-1

Dolečková, I., Kušnierik, P., Berka, V., Šimek, M., Matějková, I., Prokopec, F., et al. (2026). Oral sodium hyaluronate improves skin hydration, barrier function and signs of aging: A randomized, double-blind, placebo-controlled trial in 150 healthy adults. Scientific Reports, 16, 2941. https://doi.org/10.1038/s41598-025-32758-5

Feng, Y., Chen, P., Li, T., Wan, P., & Shi, R. (2024). Effects of exercise with or without β-hydroxy-β-methylbutyrate supplementation on muscle mass, muscle strength, and physical performance in patients with sarcopenia: A systematic review and meta-analysis. Frontiers in Nutrition, 11, 1460133. https://doi.org/10.3389/fnut.2024.1460133

Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., et al. (2023). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145

Gupta, A. K., Teasell, E. M., Economopoulos, V., & Mirmirani, P. (2026). GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress, 109(2). https://doi.org/10.1177/00368504261444578

Hsu, T.-F., Su, Z.-R., Hsieh, Y.-H., Wang, M.-F., Oe, M., Matsuoka, R., & Masuda, Y. (2021). Oral hyaluronan relieves wrinkles and improves dry skin: A 12-week double-blinded, placebo-controlled study. Nutrients, 13(7), 2220. https://doi.org/10.3390/nu13072220

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine. PMID: 35658024.

Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., et al. (2024a). Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial. JAMA Network Open, 7(6), e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775

Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., et al. (2024b). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-

treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine, 69, 102475. PMID: 38544798.

Jensterle Sever, M., Kovac, J., Vovk, A., Battelino, S., Battelino, T., & Janez, A. (2024). Once-weekly semaglutide and taste perception in women with obesity. Journal of the Endocrine Society, 8(Suppl 1), bvae163.013. https://doi.org/10.1210/jendso/bvae163.013

Kapan, A., Moser, O., Felsinger, R., Waldhoer, T., & Haider, S. (2025). Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study. Diabetes, Obesity and Metabolism, 27(9), 5008–5018. https://doi.org/10.1111/dom.16548

Liu, S., D'Amico, D., Shankland, E., et al. (2022). Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: A randomized clinical trial. JAMA Network Open, 5(1), e2144279. https://doi.org/10.1001/jamanetworkopen.2021.44279

Look, M., Dunn, J. P., Kushner, R. F., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720–2729. PMID: 39996356.

Malhotra, A., Grunstein, R. R., Fietze, I., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. The New England Journal of Medicine, 391(13), 1193–1205. https://doi.org/10.1056/NEJMoa2404881

Mawardi, H. H., et al. (2023). Semaglutide-associated hyposalivation: A report of case series. Medicine, 102(52), e36730. https://doi.org/10.1097/MD.0000000000036730

Mozaffarian, D., Agarwal, M., Aggarwal, M., et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, 122, 344–367. https://doi.org/10.1016/j.ajcnut.2025.04.023

Myung, S.-K., & Park, Y. (2025). Effects of collagen supplements on skin aging: A systematic review and meta-analysis of randomized controlled trials. The American Journal of Medicine, 138, 1264–1277. https://doi.org/10.1016/j.amjmed.2025.04.034

Pu, S.-Y., Huang, Y.-L., Pu, C.-M., et al. (2023). Effects of oral collagen for skin anti-aging: A systematic review and meta-analysis. Nutrients, 15(9), 2080. https://doi.org/10.3390/nu15092080

Sattar, N., et al. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): A post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. PMID: 40318682.

Takemura, N., et al. (2023). Sodium-hyaluronate-containing oral rinse for xerostomia: A randomized clinical evaluation. PMID: 36529530.

Urbina, J., Salinas-Ruiz, L. E., Valenciano, C., & Clapp, B. (2026). Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: A narrative review. Clinical Obesity, 16(1), e70070. https://doi.org/10.1111/cob.70070

Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384, 989–1002.

Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14725

SOURCE DOCUMENTS

Patent, Regulatory and Market Documents

These sources support regulatory, competitive and intellectual-property discussion. They should not be confused with peer-reviewed clinical evidence.

ClinicalTrials.gov. (2026). NCT07625202: Creatine Supplementation During GLP-1a Therapy.

ClinicalTrials.gov. (2026). NCT06885736: Resistance exercise and/or protein intervention in GLP-1-treated adults.

ClinicalTrials.gov. (2026). NCT07393360: Food for special medical purposes and appendicular skeletal muscle preservation during tirzepatide treatment.

European Union. Directive 2002/46/EC on food supplements.

European Union. Regulation (EC) No 1924/2006 on nutrition and health claims made on foods.

European Union. Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods, as amended.

European Patent Office. Decision T 1396/23: purpose-limited protection and nutritional compositions.

European Patent Office. Decision T 815/22: therapeutic character and nutritional compositions.

Food and Drug Administration. (2026). Wegovy (semaglutide) prescribing information.

Eli Lilly and Company. (2026). Zepbound (tirzepatide) US prescribing information.

Nestlé. (2025). Proprietary protein technology and nutritional products developed for consumers using GLP-1 weight-management medication.

Danone. (2026). Barclays Consumer Staples Conference / investor transcript discussing Oikos Fusion and GLP-1-oriented nutrition.

Herbalife. (2024). GLP-1 Nutrition Companion product-combination launch communication.

Reuters. (17 August 2026). Report on Nestlé R&D for muscle, hydration, appearance and appetite return associated with GLP-1 treatment and discontinuation.

Nutricia. US9961932B2. Muscle preservation in overweight or obese adults during weight-loss programmes.

US11241399B2. Essential-amino-acid, whey and creatine composition for muscle growth, repair and maintenance.

Abbott. US9241508B2. Shelf-stable nutritional emulsions containing calcium HMB.

WO2024216228A2. Gastrointestinal controlled-release compositions for satiety modulation.

— END OF PUBLICATION EDITION —

Beyond Weight Loss · Evidence reviewed up to 19 August 2026

About this book



Beyond Weight Loss argues that the next phase of obesity medicine is not simply to increase weight-loss efficacy, but to preserve physiological resilience while powerful incretin therapies reduce appetite and food intake. This monograph introduces Incretin Companion Care and proposes *Pharmacoadaptive Nutrition* as an emerging scientific discipline.

Integrating obesity medicine, clinical nutrition, exercise physiology, gastroenterology, dermatology, food technology, product development and translational strategy, it examines muscle preservation, nutritional adequacy, hydration, gastrointestinal tolerance, bone health, skin and hair integrity, transition after treatment, and the competitive and intellectual-property landscape shaping the field.

The result is a rigorous framework for improving the quality of weight loss in the GLP-1 era.

Key themes

- Nutritional Compression
- Anabolic Density
- Quality of Weight Loss
- Therapeutic Exit Readiness
- *Pharmacoadaptive Nutrition*

José M. López, BSc, MD, PhD, LLD (C)